SECOND EDITION

URINARY TRACT INFECTIONS

MOLECULAR PATHOGENESIS AND CLINICAL MANAGEMENT

EDITED BY

Matthew A. Mulvey
University of Utah School of Medicine
Salt Lake City, Utah

David J. Klumpp
Feinberg School of Medicine
Northwestern University
Chicago, Illinois

Ann E. Stapleton
University of Washington School of Medicine
University of Washington
Seattle, Washington

ASM PRESS
Washington, DC
To the memories of Walter Stamm, MD and Carleen Collins, PhD and to the courage of Richard Grady, MD and Laura Hart, MD
Contents

Contributors ix
Foreword xvii
Preface xix

I. CLINICAL ASPECTS OF URINARY TRACT INFECTIONS

1 Anatomy and Physiology of the Urinary Tract: Relation to Host Defense and Microbial Infection 3
   Duane R. Hickling, Tung-Tien Sun, and Xue-Ru Wu

2 Clinical Presentations and Epidemiology of Urinary Tract Infections 27
   Suzanne E. Geerlings

3 Diagnosis, Treatment, and Prevention of Urinary Tract Infection 41
   Paula Pietrucha-Dilanchian and Thomas M. Hooton

4 Urinary Tract Infections in Infants and Children 69
   Theresa A. Schlager

5 The Vaginal Microbiota and Urinary Tract Infection 79
   Ann E. Stapleton

6 Asymptomatic Bacteriuria and Bacterial Interference 87
   Lindsay E. Nicolle

7 Bacterial Prostatitis: Bacterial Virulence, Clinical Outcomes, and New Directions 121
   John N. Krieger and Praveen Thumbikat

8 Urosepsis: Overview of the Diagnostic and Treatment Challenges 135
   Florian M. E. Wagenlehner, Adrian Pilatz, Wolfgang Weidner, and Kurt G. Naber

II. ORIGINS AND VIRULENCE MECHANISMS OF UROPATHOGENIC BACTERIA

9 Reservoirs of Extraintestinal Pathogenic Escherichia coli 161
   Amee R. Manges and James R. Johnson

10 Origin and Dissemination of Antimicrobial Resistance among Uropathogenic Escherichia coli 179
    Lisa K. Nolan, Ganwu Li, and Catherine M. Logue
11 Population Phylogenomics of Extraintestinal Pathogenic 
*Escherichia coli* 207
Jérôme Tourret and Erick Denamur

12 Virulence and Fitness Determinants of Uropathogenic 
*Escherichia coli* 235
Sargurunathan Subashchandrabose and Harry L. T. Mobley

13 Uropathogenic *Escherichia coli*-Associated Exotoxins 263
Rodney A. Welch

14 Structure, Function, and Assembly of Adhesive Organelles 
by Uropathogenic Bacteria 277
Peter Chahales and David G. Thanassi

15 Pathoadaptive Mutations in Uropathogenic *Escherichia coli* 331
Evgeni Sokurenko

16 Invasion of Host Cells and Tissues by Uropathogenic Bacteria 359
Adam J. Lewis, Amanda C. Richards, and Matthew A. Mulvey

17 *Proteus mirabilis* and Urinary Tract Infections 383
Jessica N. Schaffer and Melanie M. Pearson

18 Epidemiology and Virulence of *Klebsiella pneumoniae* 435
Steven Clegg and Caitlin N. Murphy

19 Gram-Positive Uropathogens, Polymicrobial Urinary Tract Infection, 
and the Emerging Microbiota of the Urinary Tract 459
Kimberly A. Kline and Amanda L. Lewis

20 Integrated Pathophysiology of Pyelonephritis 503
Ferdinand X. Choong, Haris Antypas, and Agneta Richter-Dahlfors

III. HOST RESPONSES TO URINARY TRACT INFECTIONS 
AND EMERGING THERAPEUTICS

21 Susceptibility to Urinary Tract Infection: Benefits and Hazards of the 
Antibacterial Host Response 525
Ines Ambite, Karoly Nagy, Gabriela Godaly, Manoj Puthia, Björn Wullt, 
and Catharina Svanborg

22 Innate Immune Responses to Bladder Infection 555
Byron W. Hayes and Soman N. Abraham

23 Host Responses to Urinary Tract Infections and Emerging 
Therapeutics: Sensation and Pain within the Urinary Tract 565
Lori A. Birder and David J. Klumpp

24 Drug and Vaccine Development for the Treatment and Prevention of 
Urinary Tract Infections 589
Valerie P. O’Brien, Thomas J. Hannan, Hailyn V. Nielsen, 
and Scott J. Hultgren

Index 647
Contributors

Soman N. Abraham
Departments of Pathology, Molecular Genetics & Microbiology, and Immunology
Duke University Medical Center
Durham, NC 27710
Program in Emerging Infectious Diseases
Duke-National University of Singapore
Singapore 169857

Ines Ambite
Department of Microbiology, Immunology and Glycobiology
Institute of Laboratory Medicine
Lund University
Lund, S-223 62
Sweden

Haris Antypas
Swedish Medical Nanoscience Center
Department of Neuroscience
Karolinska Institutet
SE-171 77, Stockholm
Sweden

Lori A. Birder
Departments of Medicine and Pharmacology and Chemical Biology
University of Pittsburgh School of Medicine
Pittsburgh, PA 15261

Peter Chahales
Center for Infectious Diseases and Department of Molecular Genetics and Microbiology
Stony Brook University
Stony Brook, NY 11794

Ferdinand X. Choong
Swedish Medical Nanoscience Center
Department of Neuroscience
Karolinska Institutet
SE-171 77, Stockholm
Sweden
Contributors

Steven Clegg
Department of Microbiology
University of Iowa College of Medicine
Iowa City, IA 52242

Erick Denamur
UMR 1137 INSERM and Université Paris Diderot, IAME,
Sorbonne Paris Cité
75018 Paris
France

Suzanne E. Geerling
Department of Internal Medicine, Division of Infectious Diseases
Center for Infection and Immunity Amsterdam (CINIMA)
Academic Medical Center
1105 AZ Amsterdam
The Netherlands

Gabriela Godaly
Department of Microbiology, Immunology and Glycobiology
Institute of Laboratory Medicine
Lund University
Lund, S-223 62
Sweden

Thomas J. Hannan
Department of Pathology & Immunology
Washington University Medical School
St. Louis, MO 63110

Byron W. Hayes
Department of Pathology
Duke University Medical Center
Durham, NC 27710

Duane R. Hickling
Division of Urology, Ottawa Hospital Research Institute
The Ottawa Hospital, University of Ottawa
Ottawa, ON K1Y 4E9
Canada

Thomas M. Hooton
Department of Medicine
University of Miami Miller School of Medicine
Miami, FL 33136

Scott J. Hultgren
Department of Molecular Microbiology
Center for Women's Infectious Disease Research
Washington University Medical School
St. Louis, MO 63110
James R. Johnson
Infectious Diseases Section
Veterans Affairs Medical Center
Minneapolis, MN 55417
Department of Medicine
University of Minnesota
Minneapolis, MN 55455

Kimberly A. Kline
Singapore Centre on Environmental Life Sciences Engineering
School of Biological Sciences
Nanyang Technological University
Singapore 637551

David J. Klumpp
Departments of Urology and Microbiology-Immunology
Feinberg School of Medicine
Northwestern University
Chicago, IL 60610

John N. Krieger
Department of Urology
University of Washington School of Medicine
Seattle, WA 98195

Adam J. Lewis
Division of Microbiology and Immunology
Pathology Department
University of Utah School of Medicine
Salt Lake City, UT 84112

Amanda L. Lewis
Department of Molecular Microbiology
Washington University School of Medicine
St. Louis, MO 63110

Ganwu Li
Department of Veterinary Microbiology and Preventive Medicine
College of Veterinary Medicine
Iowa State University
Ames, IA 50011

Catherine M. Logue
Department of Veterinary Microbiology and Preventive Medicine
College of Veterinary Medicine
Iowa State University
Ames, IA 50011

Amee R. Manges
School of Population and Public Health
University of British Columbia
Vancouver, BC V6T 1Z3
Canada
Harry L.T. Mobley
Department of Microbiology and Immunology
University of Michigan Medical School
Ann Arbor, MI 48109

Matthew A. Mulvey
Division of Microbiology and Immunology
Pathology Department
University of Utah School of Medicine
Salt Lake City, UT 84112

Caitlin N. Murphy
Department of Microbiology
University of Iowa College of Medicine
Iowa City, IA 52242

Kurt G. Naber
Technical University
80333 Munich
Germany

Karoly Nagy
Department of Urology
South-Pest Hospital
Budapest 1204
Hungary

Lindsay E. Nicolle
Department of Internal Medicine and Medical Microbiology
University of Manitoba
Winnipeg, MB R3T 2N2
Canada

Hailyn V. Nielsen
Department of Molecular Microbiology
Center for Women's Infectious Disease Research
Washington University Medical School
St. Louis, MO 63110

Lisa K. Nolan
Department of Veterinary Microbiology and Preventive Medicine
College of Veterinary Medicine
Iowa State University
Ames, IA 50011

Valerie P. O'Brien
Department of Molecular Microbiology
Center for Women's Infectious Disease Research
Washington University Medical School
St. Louis, MO 63110
Melanie M. Pearson
Department of Microbiology
New York University Langone Medical Center
New York, NY 10016

Paula Pietrucha-Dilanchian
Department of Medicine
University of Miami Miller School of Medicine
Miami, FL 33136

Adrian Pilatz
Clinic for Urology, Pediatric Urology and Andrology
Justus-Liebig-University Gießen
D-35390 Gießen
Germany

Manoj Puthia
Department of Microbiology, Immunology and Glycobiology
Institute of Laboratory Medicine
Lund University
Lund, S-223 62
Sweden

Amanda C. Richards
Division of Microbiology and Immunology
Pathology Department
University of Utah School of Medicine
Salt Lake City, UT 84112

Agneta Richter-Dahlfors
Swedish Medical Nanoscience Center
Department of Neuroscience
Karolinska Institutet
SE-171 77, Stockholm
Sweden

Jessica N. Schaffer
Department of Microbiology
New York University Langone Medical Center
New York, NY 10016

Theresa A. Schlager
Department of Emergency Medicine
University of Virginia
Charlottesville, VA 22908

Evgeni Sokurenko
University of Washington
Seattle, WA 98195
Contributors

Ann E. Stapleton
Division of Allergy and Infectious Diseases
Department of Medicine
University of Washington
Seattle, WA 98195

Sargurunathan Subashchandrabose
Department of Microbiology and Immunology
University of Michigan Medical School
Ann Arbor, MI 48109

Tung-Tien Sun
Departments of Cell Biology, Biochemistry and Molecular Pharmacology
Departments of Dermatology and Urology
New York University School of Medicine
New York, NY 10016

Catharina Svanborg
Department of Microbiology, Immunology and Glycobiology
Institute of Laboratory Medicine
Lund University
Lund, S-223 62
Sweden

David G. Thanassi
Center for Infectious Diseases and Department of Molecular Genetics
and Microbiology
Stony Brook University
Stony Brook, NY 11794

Praveen Thumbikat
Department of Urology
Northwestern University School of Medicine
Chicago, IL 60611

Jérôme Tourret
Département d’Urologie, Néphrologie et Transplantation Groupe
Hospitalier Pitié-Salpètrière
Assistance Publique-Hôpitaux de Paris
Université Pierre et Marie Curie
UMR 1137 INSERM and Université Paris Diderot, IAME, Sorbonne Paris Cité
75018 Paris
France

Florian M.E. Wagenlehner
Clinic for Urology, Pediatric Urology and Andrology
Justus-Liebig-University Gießen
D-35390 Gießen
Germany
Wolfgang Weidner  
Clinic for Urology, Pediatric Urology and Andrology  
Justus-Liebig-University Gießen  
D-35390 Gießen  
Germany  

Rodney A. Welch  
Department of Medical Microbiology and Immunology  
University of Wisconsin School of Medicine and Public Health  
Madison, WI 53706  

Xue-Ru Wu  
Departments of Urology and Pathology  
New York University School of Medicine  
Veterans Affairs, New York Harbor Healthcare Systems, Manhattan Campus  
New York, NY 10016  

Björn Wullt  
Department of Microbiology, Immunology and Glycobiology  
Institute of Laboratory Medicine  
Lund University  
Lund, S-223 62  
Sweden
Foreword

Urinary tract infection (UTI), the second most common infection of humans after pneumonia, has likely plagued the population for as long as humans have walked the face of the earth. The inception of antibiotics provided adequate therapy but did not prevent infections from recurring. While symptoms of the infections were well documented, little was known about the primary infecting pathogen, *Escherichia coli*. In 1976, Svanborg and colleagues demonstrated that *E. coli* causing acute pyelonephritis adhered in greater numbers to uroepithelial cells (1). Further research by several groups revealed that the adherence factor P fimbria was responsible. This structure was found to be comprised of a multi-protein complex with the actual adhesin placed at the tip of the fimbria. With the advent of molecular techniques, other advances arrived quickly. For example, in 1981, Welch and colleagues demonstrated that a knock out of the hemolysin gene attenuated *E. coli* in an intraperitoneal model (2). As discoveries abounded, some 14 years later, I teamed up with infectious diseases physician John W. Warren to edit a 15-chapter book titled *Urinary Tract Infections: Molecular Pathogenesis and Clinical Management*. This treatise covered the clinical aspect of UTI (5 chapters) and the molecular mechanisms of bacterial pathogenesis of UTI (10 chapters).

Now two decades have passed, and it was essential to update this broad topic. Editors Matthew A. Mulvey, David J. Klumpp, and Ann E. Stapleton have taken on the task of a second edition. The editors assembled an all-star lineup to cover the topic of clinical aspects of UTIs in eight chapters that include the anatomical and physiological aspects of UTI, clinical presentations, diagnosis and treatment, infections in children, involvement of the vaginal microbiome, asymptomatic UTI, prostatitis, pyelonephritis, and urosepsis (the most serious complication). In the second section (12 chapters), experts deal with reservoirs of infection, antimicrobial resistance, phylogeny, virulence, and fitness factors including exotoxins, structure of adhesins, adaptive mutations, and intracellular persistence, and this section includes chapters on other important uropathogens: *Proteus mirabilis*, *Klebsiella pneumoniae*, and Gram-positive pathogens. In the final section on host responses to UTI and emerging therapeutics (4 chapters), authors summarize the host response to UTI, innate immunity, sensation and pain in the bladder, and drug and vaccine development. Overall, this volume brings us up to date on the broad topic of UTI. Those interested in these common infections, whether it be in the laboratory or the clinic, will find the second
edition of *Urinary Tract Infections: Molecular Pathogenesis and Clinical Management* an indispensable book that should be on your shelf or on your computer. It is gratifying to see this critical topic brought up to date.

Harry L. T. Mobley  
Frederick G. Novy Distinguished University Professor and Chair,  
Department of Microbiology and Immunology  
University of Michigan Medical School  
Ann Arbor, Michigan


Preface

For centuries the pain and other symptoms associated with urinary tract infections (UTIs) were erroneously ascribed to the wrath of gods, bile, phlegm, bad air, or numerous other culprits. The treatments for UTIs were at times equally off-target and included the use of bleeding and enemas, while the administration of narcotics and certain herbs provided palliative support. In the late 1800s, as evidence for the germ theory of disease mounted in the wake of Pasteur and Koch, the idea that microbes were responsible for UTIs took hold. This led to the development of more efficacious treatment options, culminating in the discovery and optimization of antibiotics that continue to this day. These achievements coincided with stunning advancements in our understanding of cellular functions and developmental processes within the urinary tract, inflammatory responses, microbiology, and the roles of both innate and adaptive host defenses. Still, despite this progress, UTIs continue to rank among the most common of infectious diseases, with most UTIs being attributable to strains of uropathogenic Escherichia coli (UPEC).

In 1996, for the first edition of this book, Harry L. T. Mobley and John W. Warren assembled an all-star cast of authors to highlight the multiple host and bacterial factors that impact the pathogenesis and treatment of UTIs. A lot has happened since, including remarkable progress in our ability to sequence and manipulate both bacterial and host genomes. The first *E. coli* genome, belonging to the nonpathogenic strain MG1655, was sequenced in 1997, followed a few years later by the urosepsis isolate and reference UPEC strain CFT073. Today, several thousand *E. coli* genomes have been sequenced, including many UPEC isolates. These data have revealed a huge amount of diversity among UPEC isolates, while also shedding light on the evolution and adaptability of uropathogens. These developments overlapped with the adoption of new, more facile approaches to manipulate UPEC genomes, greatly enhancing our ability to disrupt and functionally test specific pathogen-associated loci. This work is providing leads for the generation of more efficacious therapeutics for the treatment and prevention of UTIs.

Though powerful, antibiotics have not provided a cure-all for UTIs. Many individuals endure multiple recurrent UTIs despite antibiotic treatments, while circumstances such as catheterization render others prone to chronic infections. Many UPEC isolates are now resistant to multiple antibiotics, including some drugs that should be reserved as last resort choices. In terms of medical costs and loss of life, the rapid emergence and expansion of multidrug-resistant UPEC and related strains in recent years is considered by some to be more problem-
atic than methicillin-resistant *Staphylococcus aureus* (MRSA) was over the past two decades. The rising tide of antibiotic-resistant UPEC strains is showing no signs of subsiding, being driven in part by the overuse and misuse of antibiotics in both the clinic and in agriculture. Epidemiology informed by sequencing data is showing how antibiotic resistance and other genetic elements move among UPEC strains, facilitated by human activities such as global travel and the utilization of high-throughput animal processing and food distribution networks. To better combat UTIs, and antibiotic-resistant strains in particular, scientists are working to create effective anti-UTI vaccines and new antibiotics that have fewer off-target effects. Some researchers are optimizing the use of probiotic bacterial strains that can interfere with UPEC colonization of the urinary tract, while others aim to develop antivirulence strategies that modify virulence mechanisms and host responses rather than the bacteria themselves. The realization that UPEC can act as facultative intracellular pathogens in both humans and mice is also spurring the development of new treatment approaches while at the same time challenging long-held views concerning the etiology of chronic and recurrent UTIs.

Advances in bacterial genomics have been complemented by the development of new approaches to identify UTI susceptibility factors in human populations. This work, coupled with robust UTI model systems, is beginning to explain why some individuals are more prone to UTIs, making links with innate host defense regulators, adaptive immunity, inflammatory responses, and pain perception within the urinary tract. Clinically, we are gaining a much more complete understanding of the host and bacterial factors that contribute to the onset and progression of UTIs, as well as variables that can confound treatments. These variables include patient age, sex, and catheterization, as well as the makeup of protective microbial communities within the vaginal microbiota, the gut, and potentially even the bladder itself.

In this book, leading experts have reviewed the clinical diagnostics and management of UTIs in adults and children, along with associated complications such as urosepsis and prostatitis. In other chapters we take a detailed look at the origins of UPEC and associated antibiotic-resistance factors, with consideration of bacterial population dynamics, genome architecture, and evolution. The mechanisms by which uropathogens colonize the urinary tract and cause disease are thoroughly examined, with analysis of the adhesive organelles and myriad other bacterial and host factors that affect UPEC survival and virulence within the urinary tract. This includes an assessment of innate and adaptive host responses that are triggered during the course of a UTI, and the protective effects of microbial communities within the urogenital tract. The molecular biology and clinical importance of other uropathogens, including *Klebsiella pneumoniae*, *Proteus mirabilis*, and Gram-positive opportunists such as *S. aureus*, are also discussed in detail. Finally, we turn our attention to emerging antibacterial therapeutics, including the use of probiotics and bacterial interference measures. Much of the information presented in the following pages builds on work that was just coming to light when the first edition of this book was published nearly 2 decades ago. We are eager to see where the next 20 years take the field and hope that this new book, like the first edition, serves as both a resource for the community and a stimulus for future research endeavors.

Matthew A. Mulvey
David J. Klumpp
Ann E. Stapleton
ABC transporters, 237, 241, 573
Klebsiella pneumoniae, 440
Proteus mirabilis, 414–416
Staphylococcus aureus, 465
Abdominal stoma conduit, bacteriuria and, 93
Abscess
perirenal, 150
prostatic, 151
renal, 150
Accidental pathogen, 332
Ace, 301–304, 306, 466–467
Acetylcholine, 572–573
Acinetobacter baumannii, 180
ACTH (adrenocorticotrophic hormone), 138–139
Actinobacteria (phylum), 473, 476, 478, 480
Actinobaculum, 473–477, 482–484
Actinomyces, 478, 484
Activator protein 1 (AP-1), 525
Acute kidney injury (AKI), 513–514
Adaptive immunity
involvement in UTI, 543
recurrent UTI and, 610–611
Adenovirus, acute hemorrhagic cystitis and, 70
Adherence
interplay between adherence and motility, 245
in renal tubule, 506–507
Adherence factors. See Adhesins
Adhesins, 277–312
E. coli, 70–71
prostatitis isolates, 125–131
uropathogenic E. coli (UPEC), 592–599
Enterococcus, 466
Gram-negative uropathogens, 279–301
autotransporters, 293–300
Iha, 300
pili, 279–293
TosA, 300–301
Gram-positive uropathogens, 281, 301–311
EfbA, 307
MSCRAMMs, 301–307
pili, 307–311
Klebsiella pneumoniae, 442–445
overview, 277–279
pathoadaptive mutation and, 341–343
prostatitis isolates, 125–131
Staphylococcus saprophyticus, 463–464
as virulence factors, 334–335
Adjuvants, vaccine, 615–616
Adrenocorticotropic hormone (ACTH), 138–139
Aerobactin, 126, 129, 238–239, 440, 602
Aerococcus, 472–473, 484
Aeromonas hydrophila aerolysin, 268–269
Afa/Dr family of pili, 281, 283–284
Afferent nerves, 567–569
Ag43, 298–299, 534
aggR gene, 125
Aging female
anatomy and physiology, 13–14
asymptomatic bacteriuria
diagnosis, 89
incidence, 93–94
microbiology of, 99
prevalence, 92, 94–95
immune breakdown in, 560
incidence of UTI, 79
prevalence of UTI, 13–14
Aging male, asymptomatic bacteriuria in
diagnosis, 89
incidence, 93–94
microbiology of, 99
prevalence, 92, 95
Agmatine, Proteus mirabilis swarming and, 397
AIDA-I, 293, 295
AipA autotransporter, 412
AKI (acute kidney injury), 513–514
Akt, 268
Algorithm, for management of urosepsis, 148–150
Allelic variation under positive selection, 214–215
Alldynia, 577–583
Alloscardovia omnicolens, 478
α-hemolysin (Hly), 126, 128–129, 246, 253, 264–269
host response to, 507–508
mechanism, 267–269
renal damage and, 603–604
structure, 266–267
toxoid vaccine, 620
uropathogenic E. coli (UPEC), 264–269, 507–508
as virulence factor, 264–266
α-keto acids, 414
Aluminum-based adjuvants, 615
Downloaded from www.asmscience.org by
IP: 54.70.40.11
On: Thu, 06 Jun 2019 08:30:27
Ambient temperature fimbria (ATF), 409
Amikacin
  origin of, 195
  resistance, 196
Aminoglycoside acetyltransferase, 191
Aminoglycosides
  for catheter-associated UTI, 34
  indications, 195
  mechanism of action, 196
  origin of, 195
  resistance, 144, 591
    mechanisms, 196
    prevalence, 196
  side effects, 195
  for uncomplicated pyelonephritis, 54
  for urosepsis, 141–143, 146
  for UTI in children, 74
Amoxicillin
  for asymptomatic bacteriuria, 106
  resistance, 58
Amoxicillin-clavulanic acid
  for asymptomatic bacteriuria, 106
  for ESBL-producing E. coli, 49
  for pyelonephritis during pregnancy, 31
  for uncomplicated cystitis, 51–52
  for UTI during pregnancy, 31
  for UTI in children, 74
Ampicillin resistance, 124, 145
Amplification of gene copies, 337
Amygdala, 582
Anaerococcus, 483
  A. lactolyticus, 482
Analgesia in the bladder, bacterial, 580, 582–583
Anatomy, 3–18
  abnormalities, 10–14
    in aging female, 13–14
    asymptomatic bacteriuria and, 100
    bladder-outlet obstruction, 12–13
    calyceal diverticula, 11
    in children, 71
    medullary sponge kidney, 10–11
    pelvic anatomy, 13
    ureteral obstruction, 11–12
    vesicoureteric reflux, 12
bladder, 4–5
  microscopic, 6–8
  upper urinary-collecting system, 4
ureterovesical junction, 4, 5
urethra, 5–6
vagina, 6
Animal models, for polymicrobial UTI, 461–462
Anterior vaginal-wall prolapse (cystocele), 14
Antibacterial peptides, UTI susceptibility and, 538
Antibiotic prophylaxis. See Antimicrobial prophylaxis
Antibiotics. See Antimicrobial(s)
Corynebacterium urealyticum, 473
defined, 87
deliberate establishment of, 542
in diabetics, 34–35
diagnosis, 88–91
aspiration samples, 90
catheter specimens, 90
inflammatory markers, 90–91
in men, 89–90
pyuria, 90–91
quantitative urine culture, 88
voided urine specimens, 88–90
in women, 88–89
differential diagnosis, 543–544
epidemiology, 91–94
incidence, 93–94
prevalence, 36, 91–93, 529
group B Streptococcus, 469–470
innate immune system and, 561
microbiology of, 97–100
catheterized patients, 99–100
diabetic women, 98–99
healthy women, 98
infants and children, 98
institutionalized elderly, 99
older women and men, 99
pregnant women, 98
as model for pathoadaptive mutation in UPEC, 339–340
molecular characteristics of susceptibility, 529, 532, 534, 539–541
morbidity and mortality, 100–104
after invasive genitourinary procedures, 104
catheterized patients, 103–104
diabetic women, 101–102
elderly patients, 102–103
healthy women, 101
infants and children, 100–101
pregnant women, 102
mutation in strains, 345–346
natural history, 97–104
microbiology, 97–100
morbidity and mortality, 100–104
overview, 28–29, 87
pathogenesis, 94–97
host factors, 94–95
organism factors, 95–97
in pregnant women, 31, 469–470, 611
prevalence of, 36, 91–93, 529
Proteus mirabilis, 383
reductive evolution in, 529
screening for and treatment of, 104–110
after invasive genitourinary procedures, 109
children, 104–105
diabetic patients, 107
elderly institutionalized patients, 107
indwelling urethral catheter patients, 107–108
older women, 107
pregnant women, 105–107
renal transplant patients, 109–110
spinal cord injury patients, 109
in vivo evolution of E. coli strains, 215
ATF (ambient temperature fimbria), 409
Atopobium, 483
ATP, as autocrine mediator, 573–574
Atrophic vaginitis, 82
Attachment inhibitors, 60, 542
Attenuated vaccines, 619
Augmentation cystoplasty, bacteriuria and, 93
AUM (asymmetric unit membrane), 365
Autotransporter toxins, 247
Autotransporters, 248–249, 271, 293–300, 534
functions in uropathogenic E. coli (UPEC), 298–300
Ag43, 298–299
FdeC, 300
UpaB, 299
UpaG, 299
UpaH, 299
overview, 293–295
Proteus mirabilis, 411–412
secretion pathway, 296–298
structure, 295–296
Avian pathogenic E. coli (APEC), 166, 168, 208
antimicrobial resistance, 183–187, 197
relationship to NMEC and UPEC strains, 216
sequencing of O1:K1:H7 strain, 212
Bacillus cereus pili, 308
Bacterial interference, 110–111
Bacterial prostatitis. See Prostatitis
Bacterial spectrum in urosepsis, 143–144
Bacterial vaginosis (BV), 82, 471–472, 477, 480, 482–483, 485
Bacteriuria
asymptomatic, 28–29, 45, 55
catheter-associated, 32–33, 460
Gardnerella vaginalis, 477
interpretation of urine culture results, 44–45
microbiology of, 97–100
natural history of, 97–104
patterns of response to therapy, 35
in pregnancy, 15, 469–470
in prostatitis, 122, 124
rapid detection strategies, 45
threshold for diagnosis, 27
Bacteroïdes, 479, 482
Bam complex, 297–298
BarA-UvrY two-component system, 601
Barrier function, urothelial, 569
Bedwetting, 72
Behavioral risk factors for asymptomatic bacteriuria, 94
Benign prostatic hyperplasia (BPH) and bladder-outlet obstruction, 13
β-defensin, 542, 556
β-hemolysin, group B Streptococcus, 471
Beta-lactam antibiotics
mode of action of, 191
recurrence of UTI associated with, 82
resistance
mechanism, 192
prevalence, 192–193
for uncomplicated cystitis, 50–52
for uncomplicated pyelonephritis, 53–54
for urosepsis, 141–142
for UTI during pregnancy, 31
β-lactam inhibitor (BLI), for urosepsis, 146
β-lactamases, 180, 192–193
extended-spectrum beta lactamases (ESBL), 28, 49, 74, 162–163, 165–166, 168, 192
New Delhi metallo (NDM) β-lactamases, 163, 193, 214
Biarylmannose-derivative FimH antagonists, 605–606
Bifidobacterium, 478, 483
Biofilms, 90, 95, 97
catheter-associated bacteria, 460–462
CAUTI and, 605, 609
curl, 247
Enterococcus, 466–467, 604–605, 609
Klebsiella pneumoniae, 436, 444–448
matrix composition, 247
prevention of urinary catheter biofilm formation, 421–422
Proteus mirabilis, 385, 405–406, 417, 419, 421–422
Staphylococcus epidermidis, 465
uropathogenic E. coli (UPEC), 247–248
gene expression within, 248
inhibition of formation, 248
regulation of formation, 248
in urosepsis, 143
Bladder
anatomy, 4–5
diabetic cystopathy, 14
filling and emptying, neural control of, 567–568
micturition cycle, 9–10
neurogenic, 42, 71, 218
primary bladder-neck obstruction (PBNO), 16
urothelium, 7
Bladder cells, bacterial invasion of, 360–371
Bladder epithelial cells, 556–557
Bordetella pertussis, 293, 296
Bruton’s tyrosine kinase (BTK), 531
BV. See Bacterial vaginosis
“By-product of commensalism” hypothesis, 224
Cadherin, 570
Calcitonin gene-related peptide (CGRP), 568, 572
Calcium (Ca++) signaling, 508
Calyceal diverticula, 11
Calyces, 4
Candida spp., asymptomatic bacteriuria and, 97
Capsule
E. coli prostatitis isolates, 125–128
group B Streptococcus, 471
group II type, 248, 249
Klebsiella pneumoniae, 436–439
K1-type, 249
Proteus mirabilis swarming and, 395–396
shift in antigenicity, 338
Staphylococcus saprophyticus, 464
uropathogenic E. coli (UPEC), 248, 249–250
Carbapenem
resistance, 144, 448
for urosepsis, 146
CARS (counter-regulatory anti-inflammatory response syndrome), 138
CAS (chrome azul S) assay, 414, 417
Caspases, 576
Cathelicidin, 370, 509–510, 538, 556
Catheter-acquired bacteriuria
morbidity, 103–104
treatment, 107–108
Catheter-associated urinary tract infections (CAUTIs)
biofilms and, 460–462, 605, 609
daily risk, 590
Enterococcus faecalis, 306, 310–311, 461, 466–469, 604–605, 609
Escherichia coli strains infecting, 218
Gram-positive uropathogens, 460–462, 465
Klebsiella pneumoniae, 435–436, 445, 448–450
overview, 32–34
percentage of health care-associated infections, 590
polymicrobial, 462
prevention using probiotic E. coli, 561
Proteus mirabilis, 384, 385, 419–422
role of adherence and biofilm formation in, 605
Staphylococcus epidermidis, 465
treatment, 33–34
Catheterization
clean intermittent catheterization (CIC), for neurologic patients, 17
risk increase for asymptomatic bacteriuria, 95
Catheters
bacterial interferences and, 110–111
biofilms on, 90, 95, 97, 447–448
indwelling, 32–34, 93
bacterial interference, 111
bacteriuria, 95, 103, 107–108
obstruction, 385
prevention of urinary catheter biofilm formation, 421–422
silver-coated, 197
urine samples for asymptomatic bacteriuria
diagnosis, 90
Cats, as ExPEC reservoir, 165–166
Cavernitis, 151
CCLs, 535
cma, 396
CDC42, 533
Cefixime, for bacterial prostatitis, 124–125
Cefotaxime resistance, 144–145, 192
Ceftazidime resistance, 144
Ceftriaxone, for uncomplicated pyelonephritis, 54
Cell membrane receptors, genetic variants affecting, 528
Cell-cell communication, 251
Cellulose metabolism, by Klebsiella pneumoniae, 448
Cellular invasion, by Proteus mirabilis, 399–400
Central nervous system circuits in cystitis pain, 581–582
Cephalexin
for asymptomatic bacteriuria, 106
for prophylaxis, 57
Cephaporphin
for pyelonephritis during pregnancy, 31
resistance, 49, 144, 591
for urosepsis, 146
for UTI in children, 74
Cephalothin resistance, 124
Ceramide, 289, 532
CGRP (calcitonin gene-related peptide), 568, 572
Chaperone/usher (CU) assembled pili, 243, 251, 279–289
assembly at outer membrane, 285–286
chaperone-subunit complex formation, 284–285
fiber, 281–283
functions of, 287–289
gene clusters, 282
inhibitors, 607
Klebsiella pneumoniae, 443
P pilus, 289
pilus usher, 286–287
structure, 281–284
type 1 pilus, 287–288
Chemotaxis, 245
Children
asymptomatic bacteriuria
diagnosis, 88
incidence, 93
microbiology, 99
morbidity, 100–101
prevalence, 92
screening, 104–105
treatment, 104–105
urinary tract infection in, 69–75
clinical presentation, 72
diagnosis, 72–73
epidemiology, 69–70
imaging, 74–75
laboratory work-up, 72–73
management and treatment, 73–74
overview, 30–31
pathogenesis, 70–71
prophylaxis, 75
treatment, 31
vesicoureteral reflux, 70–72
vesicoureteral reflux, 70–72, 100, 105
Chitosan, as bladder cell exfoliant, 372
Chrome azul S (CAS) assay, 414, 417
Chronic pelvic pain syndrome (CPPS)
E. coli in, 129–132
pathogenesis of, 131–132
virulence factors in, 130
Chronic prostatitis/chronic pelvic pain syndrome
(CP/CPPS), 36
Chronic urinary retention, 13
ChuA, 239, 240
Ciprofloxacin
for asymptomatic bacteriuria, 108
for prophylaxis, 57–58
resistance, 144–145, 191, 476, 591
for uncomplicated cystitis, 50–52
for uncomplicated pyelonephritis, 53–54
for urosepsis, 142–147
Circumcision, 71
Citrobacter
asymptomatic bacteriuria, 97
C. freundii
adhesins, 280
intracellular bacterial communities (IBCs), 600
Clathrin-coated pits, 595
Claudins, 566
Clean intermittent catheterization (CIC), for
neurologic patients, 17
Clean-catch technique, 43–44
ClfA, 301–302, 304
Clinical diagnosis of urinary tract infection, 41–42
Clinical syndromes
acute pyelonephritis, 30
asymptomatic bacteriuria, 28–29
complicated UTI, 28–29
prostatitis, 30
special patient groups
catheterized patients, 32–34
children, 30–31
diabetes mellitus, 34–35
men, 31
pregnant women, 31–32
uncomplicated cystitis, 29
urosepsis, 30
Clostridium difficile
antimicrobial resistance, 180
colitis, 591
diarrhea, UTI prophylaxis and, 58
Clot formation, in pyelonephritis, 511–512
Clue cells, 480, 485
CmFA, 395–396
Cna, 301–302, 304
CNF-1. See Cytotoxic necrotizing factor-1
Coagulase-negative staphylococci, asymptomatic bacteriuria and, 97
Colibactin, 126, 128–129
Colicin, 126
Collagen hug model of ligand binding, 302–304
Colony morphology, variation in E. coli, 337–338
Commensals, 529
as opportunistic pathogens, 332
virulence as by-product of commensalism, 224
Community-acquired UTI, 28
Companion animal reservoirs of ExPEC, 165–166
Comparative genomics, of UPEC strains, 211
Compensatory endocytosis, 365
Complement-mediated phagocytosis, 556–557
Complicated urinary tract infection (UTI) defined, 28, 460
Enterococcus faecalis, 604–605
Gram-positive uropathogens, 460
overview of clinical syndrome, 29–30
treatment, 29–30
Condom catheter, 89, 95
Conjugate vaccines, 619–620
Conjugative plasmids, 180, 182
Conjugative transposons, 182
Contamination, of voided urine sample, 43–44
Contraceptive method, effect on vaginal microbiota, 82
Convergent evolution, 350
Corticotropin-releasing factor/hormone, 139, 568, 571–572
Corynebacterium, 484
C. diptheriae pili, 278, 307, 308, 310
C. renale pili, 278
C. urealyticum, 473
Cost of urinary tract infections, 36–37, 79–80, 236, 556
Counter-regulatory anti-inflammatory response syndrome (CARS), 138
Cox2, 537–538
COX-2 (cyclooxygenase-2) inhibitors, 558
CP293, 618–619
CP/CPPS (chronic prostatitis/chronic pelvic pain syndrome), 36
cps gene cluster, 438
Cpx, 601
Cranberry, 55, 75, 372, 515, 608–609
Crosstalk, molecular, 513
csg gene cluster, 290–292
CsrA, 394
CTX-M
CTX-M-1, 168
CTX-M-15, 162–163
CTX-M-32, 168
Escherichia coli, 213–215
extended-spectrum beta-lactamase (ESBL), 49, 192
CueO, 339
Culture-negative urine, 481
Curli, 247, 278, 289–293
assembly machinery, 292
assembly on the bacterial surface, 291–292
extracellular nucleation-precipitation, 292
functions in UPEC, 292–293
structure, 292–293
as virulence factor, 534
Curlicide, 607
CXCL1, 559
CXCL2, 537, 559–560
CXCL8, 534–535
CXCR1, 504, 508, 535, 540, 560
CXCR2, 535
Cyclic adenosine monophosphate (cAMP) and UPEC expulsion, 599
Cyclooxygenase-2 (COX-2) inhibitors, 558, 603
Cyclophosphamide-induced cystitis, 581
Cystic fibrosis, 338
Cystitis
acute cystitis, modeling the outcomes of, 602–603
acute hemorrhagic cystitis, 70
acute uncomplicated cystitis
antimicrobial treatment, 29
clinical diagnosis, 42
overview, 29
treatment, 49–53
clinical diagnosis, 42
clinical picture, 150
CNS circuits in pain, 581–582
Corynebacterium urealyticum encrusting cystitis, 473
cyclophosphamide-induced cystitis, 581
dipstick diagnosis, 46–47
incidence, 36
interpretation of urine culture results, 44
modeling outcomes of acute, 602–603
polymicrobial, 481
symptoms, 29, 527, 589
Cystocele, 14
Cytokines
as markers of the septic response, 138
pro-inflammatory, 138–139
response to infection, 534–535
Cytolethal-distending toxin 1, 126
DAF (decay-accelerating factor), 342–343
DamX, 371
Debilitated patients, *Escherichia coli* strains infecting, 218
Decay-accelerating factor (DAF), 342–343
Defensins, 439, 509, 538
DegP periplasmic protease, 285
Denaturing high-performance liquid chromatography (DHPLC), 482
Dendritic-cell maturation, *Klebsiella pneumoniae* induction of, 439
Detrusor-external sphincter dyssynergia (DESD), 16–17
Dexamethasone, 53
DHFR (dihydrofolate reductase), 182, 189
DHPLC (denaturing high-performance liquid chromatography), 482
DHPPP (dihydro-6-hydroxymethylpterin-pyrophosphate), 189
DHP (dihydropteroate synthase), 189
Diabetes mellitus, 14–15
asymptomatic bacteriuria, 95
diagnosis, 89
microbiology of, 98–99
morbidity, 101–102
prevalence, 92
Dipterus-external sphincter dyssynergia (DESD), 16–17
DMSA (dimercaptosuccinic acid) scans, 527
Dipsticks, 43, 46–48, 73, 460
DisA decarboxylase, 393–394
D-mannose, 60
DMSA (dimercaptosuccinic acid) scans, 527
DNA gyrase, 190, 336
DNA microarrays, 254
DNA topoisomerase IV, 190
DNA-mismatch repair genes, 338–339
Dock, lock, and latch model, 304
Dogs, as ExPEC reservoir, 165–166
Doppler ultrasonography, for renal scarring detection, 75
Doripenem, 143
Dorsal-root ganglia, 567
Doxycycline, for bacterial prostatitis, 124–125
Dr adhesins
mutations in, 342–343
vaccine targeting, 622
DraE adhesin, 343
DsdA, 339
Dynamin2, 367
Dysfunctional voiding, 16
Dysuria
in cystitis, 29
in prostatitis, 122, 124
EAEC (enteroaggregative *Escherichia coli*), quorum-sensing system in, 251
EibD autotransporter, 296
Elderly individuals
immune breakdown in, 560
invasive group B *Streptococcus* disease in, 470
Encopresis, 30
Encrusting cystitis, *Corynebacterium urealyticum* and, 473
Endocytosis
compensatory, 365
urothelial, 569
Dibekacin, origin of, 195
Dienes line, 401–402
Differential diagnosis, molecular tools for, 543–544
Dihydrofolate reductase (DHFR), 182, 189
Dihydro-6-hydroxymethylpterin-pyrophosphate (DHPPP), 189
Dihydropirroloate synthase (DHPS), 189
Dimercaptosuccinic acid (DMSA) scans, 527
Dipsticks, 43, 46–48, 73, 460
DisA decarboxylase, 393–394
D-mannose, 60
DMSA (dimercaptosuccinic acid) scans, 527
DNA gyrase, 190, 336
DNA microarrays, 254
DNA topoisomerase IV, 190
DNA-mismatch repair genes, 338–339
Dock, lock, and latch model, 304
Dogs, as ExPEC reservoir, 165–166
Doppler ultrasonography, for renal scarring detection, 75
Doripenem, 143
Dorsal-root ganglia, 567
Doxycycline, for bacterial prostatitis, 124–125
Dr adhesins
mutations in, 342–343
vaccine targeting, 622
DraE adhesin, 343
DsdA, 339
Dynamin2, 367
Dysfunctional voiding, 16
Dysuria
in cystitis, 29
in prostatitis, 122, 124
EAEC (enteroaggregative *Escherichia coli*), quorum-sensing system in, 251
EibD autotransporter, 296
Elderly individuals
immune breakdown in, 560
invasive group B *Streptococcus* disease in, 470
Encopresis, 30
Encrusting cystitis, *Corynebacterium urealyticum* and, 473
Endocytosis
compensatory, 365
urothelial, 569
Dibekacin, origin of, 195
Dienes line, 401–402
Differential diagnosis, molecular tools for, 543–544
Dihydrofolate reductase (DHFR), 182, 189
Dihydro-6-hydroxymethylpterin-pyrophosphate (DHPPP), 189
Dihydropirroloate synthase (DHPS), 189
Dimercaptosuccinic acid (DMSA) scans, 527
Dipsticks, 43, 46–48, 73, 460
DisA decarboxylase, 393–394
D-mannose, 60
DMSA (dimercaptosuccinic acid) scans, 527
DNA gyrase, 190, 336
DNA microarrays, 254
DNA topoisomerase IV, 190
DNA-mismatch repair genes, 338–339
Dock, lock, and latch model, 304
Dogs, as ExPEC reservoir, 165–166
Doppler ultrasonography, for renal scarring detection, 75
Doripenem, 143
Dorsal-root ganglia, 567
Doxycycline, for bacterial prostatitis, 124–125
Dr adhesins
mutations in, 342–343
vaccine targeting, 622
DraE adhesin, 343
DsdA, 339
Dynamin2, 367
Dysfunctional voiding, 16
Dysuria
in cystitis, 29
in prostatitis, 122, 124
EAEC (enteroaggregative *Escherichia coli*), quorum-sensing system in, 251
EibD autotransporter, 296
Elderly individuals
immune breakdown in, 560
invasive group B *Streptococcus* disease in, 470
Encopresis, 30
Encrusting cystitis, *Corynebacterium urealyticum* and, 473
Endocytosis
compensatory, 365
urothelial, 569
Endothelial NOS (eNOS), 573
Endotoxin, 138
endotoxia, 611
vaccine, 619
Enterococcal aggregation Escherichia coli (EAEC) prostatitis, 125
Enterobacter
antimicrobial resistance, 48
E. cloacae
antimicrobial resistance, 145
pyelonephritis, 150
intracellular bacterial communities (IBCs), 600
urinary tract infection in children, 70
Enterobacteriaceae
asymptomatic bacteriuria, 97
fluoroquinolone resistance, 190
incompatibility groups, 187
plasmid replicons, 187
UTI in children, 70
Enterobacterial-repetitive intergenic-consensus (ERIC) polymerase chain reaction (PCR), 213, 217
Enterobactin, 238–239, 534, 602
Enterochelin, 440
Enterococcus, 459, 461–462, 466–469
asymptomatic bacteriuria, 97
catheter-associated UTI (CAUTI), 461, 466–469
E. faecalis
Ace, 301–304, 306
adhesins, 281, 301–302, 307–311
antimicrobial resistance, 144–145
biofilm, 604–605, 609
catheter-associated UTI (CAUTI), 306, 310–311, 461, 591, 604–605, 609
Ebp pilus, 605
inhibition biofilm formation, 248
invasion of host cells, 372
laboratory model for study of, 461
nosocomial UTIs, 301, 306
pili, 307–311, 467, 596
sortases, 604–605
urine contamination, 480
UTI, 459, 461–462, 466–469
E. faecium, 604
adhesins, 281
antimicrobial resistance, 144–145
pili, 307–311
epidemiology of UTI, 466
frequency of urinary tract colonization, 504
immune responses to, 467–469
urosepsis, 143
UTI in children, 70
vaccines, 624
virulence factors, 466–467
Enterohemorrhagic E. coli (EHEC), quorum-sensing system in, 251
Enteropathogenic Escherichia coli (EPEC) intimin protein, 300
Environmental reservoirs of ExPEC, 164–165
EPEC (enteropathogenic Escherichia coli) intimin protein, 300
Epidemiology, 36–37
asymptomatic bacteriuria, 91–94
incidence, 93–94
prevalence, 91–93
ExPEC strains, 215–219
urinary tract infection, 590, 592
in children, 69–70
of enterococcal, 466
group B Streptococcus UTI, 469
polymicrobial, 461–462
Staphylococcus saprophyticus, 462–463
urosepsis, 136, 137
Epidermal growth-factor receptor (EGFR), 569–570
Epididymitis, clinical picture, 151
Epithelial cells, bladder, 556–557
Epithelial integrity, infection-associated breakdown of, 511
EQUC (expanded-quantitative urine culture), 484
ERIC (enterobacterial-repetitive intergenic-consensus) polymerase chain reaction (PCR), 213, 217
Erk, 581
ESBL (extended-spectrum beta lactamases), 28, 49, 74, 162–163, 165–166, 168, 192
Escherichia coli. See also Extraintestinal pathogenic E. coli; Uropathogenic Escherichia coli
acute hemorrhagic cystitis, 70
adhesions, 280, 281, 293, 295, 334–335, 341–343
AIDA-I, 293, 295
α-hemolysin (Hly), 126, 128–129, 246, 253, 264–269, 507–508
analgesic activity, 580, 582–583
antimicrobial resistance, 48–49, 124, 144–146, 162–167, 170, 179–198
asymptomatic bacteriuria, 28, 71, 88, 95–97, 97–100, 561
avian pathogenic E. coli (APEC), 166, 168, 208
antimicrobial resistance, 183–187, 197
relationship to NMEC and UPEC strains, 216
sequencing of O1:K1:H7 strain, 212
bacterial interference, 110–111
biofilms, 143
catheter-associated UTI (CAUTI), 33
chromosome, 209
colony type variations, 337–338
commensal strains, 208
curli, 289–293
in diabetics, 14–15
diseases caused by, 208
eco-evo categories of, 332
enteroaggregative E. coli (EAEC) prostatitis, 125
enterohemorrhagic *E. coli* (EHEC), quorum-sensing system in, 251
enteropathogenic *E. coli* (EPEC) intimin protein, 300
epidemiology, 36
extended-spectrum beta lactamases (ESBL), 28, 49, 74, 74–162, 165–166, 168
fimbriae
  - innate immune activation, 532–534
  - P fimbriae, 532–533
  - type 1 fimbriae, 533–534
genetic population structure, 208–209
horizontal gene transfer, 335
lactobacilli inhibition of, 81
multidrug-resistant strains, 213–214, 556
NDM-1 β-lactamase, 193
neonatal meningitis *Escherichia coli* (NMEC), 208, 216, 218–219
number of cells on Earth, 208
periurethral colonization, 70
phylogenetic groups, 128
pili, 280–281
polymicrobial extraintestinal infections, 221–223
population-genetics structure of *E. coli* species, 208–209
probiotic, 333–334, 561
prostatitis, 121–132, 151
pyelonephritis, 150
renal and perirenal abscess, 151
sexual transmission, 333
swarming by, 389
urosepsis, 143
UTI in children, 74
Variome database, 351
virulence factors, 96
in vivo evolution of strains, 215
*Escherichia fergusonii*, 212
Esp, 466
EstA autotransporter, 295–296
Estradiol-releasing vaginal ring (Estring), 82
Estriol cream, 609
Estrogen
  - decline of contributing factor to UTI, 560–561
  - effect of loss on vaginal microbiota, 81–82
  - lactobacilli effect on, 14
  - supplementation, 561, 609
  - therapy, 609
  - urothelial structure, effect on, 570
Estrogen cream, 36, 82, 609
Estrogen-replacement therapy, 609
Evolution
  - allelic variation under positive selection, 214–215
  - “by-product of commensalism” hypothesis, 224
  - co-evolution of bacteria and host, 541
ExPEC virulence, 224
host environment and, 529
molecular-convergent, 350
pathoadaptive mutations in UPEC, 331
reductive, 529
role of recombination in, 209
in vivo evolution of *E. coli* strains, 215
Exfoliation
  - of bladder epithelial cells, 557
  - as host defense, 370
Exocytosis, 573–574
  - stretch-induced, 569, 573
vesicular, 573
Expanded-quantitative urine culture (EQUC), 484
Extended-spectrum beta lactamases (ESBL), 28, 49, 74, 74–162, 165–166, 168, 192
External sphincterotomy, 17
External-urethral sphincter, 6, 9, 16–17
Extraintestinal pathogenic *Escherichia coli* (ExPEC), 161–170. See also Uropathogenic *Escherichia coli*
avian pathogenic *E. coli* (APEC), 166
companion animal reservoirs, 165–166
environmental reservoirs, 164–165
foodborne reservoirs, 167–169
  - beef and cattle sources, 169
  - pork and pig sources, 169
  - poultry sources, 167–169
human reservoir, 163–164
important lineages, 162–163
mutation rate, 214–215
population phylogenomics, 207–225
  - allelic variation under positive selection, 214–215
  - “by-product of commensalism” hypothesis, 224
  - CGA (clonal group A), 212–213, 217, 219, 221
  - clinical relevance of intrinsic virulence, 219–221
  - diversity within clones, 215
  - epidemiologic data based on proxy markers, 215–219
  - infants, UPEC and NMEC strains infecting, 218–219
  - origin of UPEC strains, 216–217
  - phylogenetics, 209–212
  - polymicrobial infections, 221–223
  - population-genetics structure, 208–209
  - relatedness of UPEC, NMEC, and APEC strains, 216
  - strains infecting debilitated patients, 218
  - UPEC-specific genes, search for, 211–214
  - virulence factors, phylogeny and, 217–218
  - public health perspectives, 169–170
UpaG autotransporter, 299
virulence factors, 123, 125–128, 208
F-actin, 366, 369
FIC fimbriae, 96, 125–126, 128, 244
FdeC, 300, 623
Febrile urinary tract infections, 29–30, 543, 591 in children, 69
clinical presentation, 72
Female-genital cutting (FGM), 460
Fenobam, 582
Ferric citrate transport, in *Proteus mirabilis*, 414–415
Ferric iron uptake, in *Klebsiella pneumoniae*, 440
Ferric-uptake regulator (Fur), 237–238, 440
Ferrous iron uptake, 240, 414–415
FGL chaperones, 285
Fibroblast-growth factor, 570
fim operon, 209, 213–214
fim switch, 507
FimB, 507
Fimbria 14 operon, *Proteus mirabilis*, 409
Fimbriae. See also Pili
ambient temperature fimbria (ATF), 409
biofilms and, 247–248
FIC, 96, 125–126, 128, 244
gene clusters, 244, 251
innate immune activation, 532–534
*Klebsiella pneumoniae*, 442–445
gene clusters, 442–444
role in virulence, 444
structure and genetics, 443–444
lack of gene expression in vivo, 253–254
mannose-resistant (MR), 402–407
motility, effect on, 245
mutations, 341–343, 346–348
origin of term, 278
P fimbriae, 7, 243–244, 243, 506–507, 532–533
phase variation, 507
pilicides, 244
Pix fimbria, 244
*Proteus mirabilis*, 14, 402–411, 623–624
ambient temperature fimbria (ATF), 409
conservation and expression of, 409–410
mannose-resistant *Klebsiella*-like (MR/K), 402–403, 407
mannose-resistant *Proteus*-like (MR/P), 402–407
*Proteus mirabilis* fimbria (PMF), 408–409
*Proteus mirabilis* P-like fimbria (PMP), 409
regulation of transition between swimming and swarming, 410–411
uroepithelial cell adhesin (UCA), 402–403, 407–408
vaccine potential of, 421
pyelonephritis and, 506–507
S fimbriae, 244, 539
synergistic effects of P and type 1 fimbriae in vivo, 506
type 1 fimbriae, 243, 245
innate immune-response activation by, 533–534
*Klebsiella pneumoniae*, 442–445
mutations, 341–342, 346–348
phase variation, 507
Salmonella, 443
synergy with P fimbriae, 506–507
uropathogenic *E. coli* (UPEC), 243, 506–507
uropathogenic *E. coli* (UPEC), 7, 242–244, 506–507, 532–533
Yad fimbria, 244
Ygi fimbria, 244
fim-gene cluster, *Klebsiella pneumoniae*, 443
FimH, 60, 71, 125, 127, 284, 287, 360–361, 365–368, 507, 533, 559
antagonists, 605–606
in *E. coli* prostatitis, 130
immunization against, 543
inhibition of attachment, 542
mediation of UPEC adherence to and invasion of urothelial cells, 595
mutations in, 341–342, 346–348
P fimbriae, 96
pathoadaptive mutation in UPEC clinical isolates, 595
phase variation, 7
uroplakin interaction, 7
urothelial dysfunction and, 575–578
vaccines targeting, 620–621
FlaA, 387–389, 398
FlaAB, 387
FlaB, 387–388, 390
FlaC, 387
FlaD, 389, 399
Flagella
ascension to kidneys and, 603
loss of expression, 338
phase variation, 7
regulation of motility in uropathogenic *E. coli* (UPEC), 242
as virulence factor, 534
Flagellin, 245, 624
*flgN*, 390
*flhA*, 390
*flhDC*, 387, 390–391, 394–395
*fliG*, 391
*fliL*, 391
*flu* gene, 298–299
Fluoroquinolones
for catheter-associated UTI (CAUTI), 33
mode of action, 190
for prophylaxis, 57–58
for prostatitis, 31
resistance, 48–49, 162, 181, 338, 591
mechanism, 190–191
prevalence, 191
side effects, 51, 58
for uncomplicated cystitis, 50–52
for uncomplicated pyelonephritis, 53–55
for urosepsis, 141–146
Focal nephritis, 150
Folk remedies, 515
Foodborne reservoirs of human ExPEC, 167–169
Forskolin, 599
Fosfomycin
for asymptomatic bacteriuria, 106
for ESBL-producing E. coli, 49
mode of action, 194
for prophylaxis, 57
for Proteus mirabilis, 419
resistance
mechanism, 194
prevalence, 194
for uncomplicated cystitis, 49, 51
Fournier’s gangrene, 151–152
frdA, 399
Fumarate, Proteus mirabilis swarming and, 397
fumC, 399
Functional analysis, pathoadaptive mutations and, 346–348
Fur (ferric-uptake regulator), 237–238, 440
“Fur boxes,” 237
Fusiform vesicles, 557, 569, 599
Fusobacteria, 482
FyuA, 240, 622
Galabiose PapG antagonists, 606–607
Gap junctions, 567, 572
Gardnerella vaginalis, 471, 477–480, 482, 485
GBS. See Group B Streptococcus
Gene activation, 336, 339–340
Gene amplification, 337
Gene cassettes, 182
Gene clusters
fimbriae, 244, 251
fimbrial in Klebsiella pneumoniae, 442
pili, 282
Gene expression
global regulators of, 250–251
Proteus mirabilis during UTI, 418–419
uropathogenic E. coli (UPEC) gene expression
in vivo, 253–254
Gene therapy, 542
Genetic drift, 337, 350
Genetic population structure, Escherichia coli, 208–209
Genetic variation, pathoadaptive evolution and, 337
Genetics
asymptomatic bacteriuria and genetic factors, 94
immunocompromise, 560
predisposition to UTIs, 17, 35
renal scarring and, 72
susceptibility, to pyelonephritis, 504
Genome evolution, role of recombination in, 209
Genome organization, Proteus mirabilis, 418
Genome sequences, for uropathogenic E. coli (UPEC) strains, 251–253
Genome stability, UPEC, 339
Genomic islands, Escherichia coli, 210–215, 252–253
Genotoxins, 129
Gentamicin
for catheter-associated UTI (CAUTI), 33
discovery, 195
resistance, 144, 145, 196
Glial cells, 569
Glomerular filtration
in pyelonephritis, 512–513
rate, urosepsis and, 140
Glutamine, Proteus mirabilis swarming and, 396
Gram-negative uropathogens, adhesins expressed by, 279–301
autotransporters, 293–300
Iha, 300
pili, 279–293
TosA, 300–301
Gram-positive uropathogens, 459–486
Actinobaculum schaali, 473–477
Aerococcus, 472–473
catheter-associated UTI (CAUTI), 460
complicated UTI, 460
Corynebacterium urealyticum, 473
Enterococcus, 459, 461–462, 466–469
catheter-associated UTI (CAUTI), 461, 466–469
epidemiology of UTI, 466
immune responses to, 467–469
virulence factors, 466–467
Gardnerella vaginalis, 471, 477–480
group B Streptococcus (GBS), 459–460, 462, 469–471
bacteriuria in pregnancy, 469–470
epidemiology, 469
immune response to, 470–471
invasive disease in elderly, 470
virulence factors, 470–471
laboratory models for study of UTI, 461
point of care diagnosis of UTI, 460
polymicrobial UTI, 461–462, 480–481
Staphylococcus saprophyticus, 459–466
epidemiology of UTI, 462–463
host response to UTI, 465–466
laboratory models of UTI, 461
polymicrobial UTI, 461
virulence factors, 463–465
uncomplicated UTI, 459
uncultivated bacterial inhabitants of the urinary tract, 481–485
urine contamination with, 480–481
Group B Streptococcus (GBS), 459–460, 462, 469–471
bacteriuria in pregnancy, 469–470
in children, 70
epidemiology, 469
immune response to, 470–471
Group B Streptococcus (GBS) (continued)

- invasive disease in elderly, 470
- treatment during pregnancy, 32
- urine contamination, 480
- UTI, 70, 459–460, 462, 469–471
- vaccine, 470
- virulence factors, 470–471

Growth in urine, 236–237
Growth promoter, 170
GspB, 463
GTPase, 514, 533

Haemophilus
- capsule biogenesis system of, 249
- H. influenzae Hia adhesin, 295–296

Hammock theory, 14
HCN3 (hyperpolarization-activated cation-3), 9

Helicobacter pylori
- Hia adhesin, 295–296

Hematuria, in prostatitis, 124

Heme uptake
- Proteus mirabilis, 414–416
- receptor-mediated, 239

Hemolysin
- α-hemolysin (Hly), 126, 128–129, 246, 253, 264–269
- host response to, 507–508
- mechanism, 267–269
- renal damage and, 603–604
- structure, 266–267
- toxoid vaccine, 620
- uropathogenic E. coli (UPEC), 264–269, 507–508
- as virulence factor, 264–266
- β-hemolysin, group B Streptococcus, 471

Proteus mirabilis, 412–413

Hia adhesin, 295–296
High-pathogenicity island (HPI), 214
Histamine, 559
Histidine, Proteus mirabilis swarming and, 397
Histone-like nucleoid structuring protein (H-Ns), 250
HmA, 239, 240, 622

Homologous recombination, gene exchange by, 335
Horizontal gene transfer (HGT), 25, 35–336, 181

Hospital-acquired UTI, 28
Host defenses, 71, 370. See also Innate immune system
- bacteriuria and, 94
- exfoliation of bladder epithelial cells, 557
- innate immune response to bladder infection, 555–562
- in pyelonephritis, 507–508

Host factor Q-beta (Hfq), 250–251
Host response to staphylococcal UTI, 465–466
HPI (high-pathogenicity island), 214

hpmA, 387–389, 391, 398–400, 412–413
Human reservoir of ExPEC, 163–164
hybB, 399
Hydrogen peroxide production by lactobacilli, 80–81

Hydronephrosis
- imaging guidelines, 74
- infected, 152
- perinatal, 71
- in pregnancy, 15
- vesicoureteral reflux with, 71

Hypercolonization phenotype, 339

Hyperglycosuria, 14

Hyperpolarization-activated cation-3 (HCN3), 9

Hypogastric nerves, 567

Hypothalamic-pituitary-adrenal axis
- stress activation of, 571
- system inflammation and, 139

Hypoxia, nephron, 511, 514

IBCs. See Intracellular bacterial communities

Ibuprofen, 52, 603

IDSA (Infectious Diseases Society of America), 48

IgA, 615–616, 618, 622, 624

IgG, 615–616, 618, 622, 624

Iha, 300, 335, 599

IL-1R-associated kinase 4 (IRAK4), 531–532

Imaging children after their first urinary tract infection, 74

Imidazolium salts, as bladder cell exfoliant, 372

Immune response. See also Innate immune response
- enterococcal UTI, 467–469
- group B Streptococcus, 470–471
- in pyelonephritis, 508–510
- to Staphylococcus saprophyticus, 466–467

Immunocompromised individuals, E. coli strains infecting, 218

Immunotherapeutic compounds, 624–625

Incidence
- in aging females, 79
- of asymptomatic bacteriuria, 93–94
- of Proteus mirabilis UTI, 384
- of recurrent urinary tract infections, 590
- of urinary tract infection, 36, 236
- of uropathogenic Escherichia coli (UPEC) UTI, 556

Incontinence, urinary-urgency, 481, 484

Inducible nitric-oxide synthase (iNOS), 573

Indwelling catheters, 32–34, 93

bacterial interference, 111
bacteriuria, 95, 103, 107–108

Infants
- asymptomatic bacteriuria
- microbiology, 99
- morbidity, 100–101

UTI in, 69–75 (See also Children)

vesicoureteral reflux, 100
Infectious Diseases Society of America (IDSA), 48

Inflammation
acute kidney injury, 513–514
in Enterococcus UTIs, 467–469
mast cells and, 559, 562
neutrophil-associated tissue damage, 558, 561–562
UTI pain and, 577–578

Inflammatory markers, in asymptomatic bacteriuria, 90–91

Infundibulum, 4

Innate immune response
bacteriuria and, 94
to bladder infection, 555–562
cellular components of, 556–560
epithelial cells, 556–557
immune breakdown, 560–561
genetic variants affecting the early, 526
in pyelonephritis, 508–510
to Staphylococcus saprophyticus, 466–467

Innate immune system
bacterial inhibitors of, 541–542
RNA polymerase II expression, 541–542
TIR-domain proteins, 541
therapeutic approaches that modify, 542–543
deliberate establishment of asymptomatic bacteriuria, 542
gene therapy, 542
receptor analogues, 542
vaccination, 543
UTI susceptibility and activation, 529–534
autotransporters, 534
curli, 534
iron acquisition systems, 534
P fimbriae, 532–533
TLR4, 531–532
toxins, 534
type 1 fimbriae, 533–534

“In-series tension receptors,” 568

Insertion sequences (IS elements), 181

Integral theory, 13–14

Integrase, 182–183

Integrins, 366–368, 372, 592

Integrins, 182–184

Interferon (IFN)-β, 537

Interferon (IFN)-γ, 513

Interferon regulatory factors (IRFs), 525, 533

Interleukins
IL-1, 138, 511, 514
IL-4, 139
IL-6, 508, 511, 514, 527, 534, 556
levels in pyelonephritis, 543
urine, 90–91
IL-8, 508, 509, 534, 543, 558
IL-10, 139, 559
IL-1β, 556

Intermittent catheterization
bacterial interference, 111

bacteriuria and, 103–104
Internal-urethral sphincter, 5
Inter-organ communication during infection, 513

Interstitial cystitis
interstitial cystitis/bladder-pain syndrome (IC/BPS), 569
urothelial damage during, 57–576

Intimin, 300

Intracellular bacterial communities (IBCs)
expulsion of UPEC, 599
formation, 599–600
Klebsiella pneumoniae, 444, 450
UPEC dispersal and further IBC formation, 600–601

Intrinsic virulence, ExPEC, 220–221

Invasin, 300

Invasion of host cells, 359–372. See also Intracellular bacterial communities
antibacterial defenses and liabilities, 370–371
fates of intracellular UPEC, 360–363
intracellular bacterial communities (IBCs), 361–364, 369–370
of kidney cells, 371
mechanisms of bladder cell invasion, 365–368
regulation of intracellular growth and persistence, 368–369
relevance to UTIs, 364–365
targeting intracellular pathogens, 372

Invasive genitourinary procedures, bacteriuria and, 104, 109

IRAK4 (IL-1R-associated kinase 4), 531–532

IreA, 240, 622

IRF3, 537, 540

IroN, 602, 622

Iron acquisition
Escherichia coli, 214, 238–239, 534, 602
ferrous iron uptake, 240
Klebsiella pneumoniae, 440–441
genetics, 440–441
role in virulence, 441
siderophore production, 440
pathogenesis, 602
Proteus mirabilis, 396, 413–416
receptor-mediated heme uptake, 239
redundant systems, 239
regulation of iron uptake, 237–238
siderophores, 238–239, 534
E. coli prostatitis, 125–129, 130
Klebsiella pneumoniae, 440–441
pathogenesis, 602
Proteus mirabilis, 414–415
uropathogenic E. coli (UPEC), 238–239, 534, 602
uropathogenic E. coli (UPEC), 238–239, 534, 602
Iron receptors as vaccine candidates, 240
IS elements (insertion sequences), 181
Ischemia, nephron, 510–511, 513–514
IutA, 240, 622
Juxtaglomerular apparatus (JGA), 513
Kanamycin resistance, 196
KguS-KguR two-component system, 601
Kidney. See also Pyelonephritis
acute kidney injury, 513–514
anatomy, 4
medullary sponge, 10–11
renal scarring, 72, 75, 100, 509, 513, 531, 540, 590, 603
UPEC ascension to and colonization of the kidneys, 603–604
Kidney cells, bacterial invasion of, 371
Klebsiella
antimicrobial resistance, 48
asymptomatic bacteriuria, 95
UTI in children, 70
Klebsiella oxytoca
antimicrobial resistance, 145
frequency of urinary tract colonization, 504
Klebsiella pneumoniae, 435–450
adhesins, 280
antimicrobial resistance, 144, 145, 448–449
asymptomatic bacteriuria, 97
biofilms, 436, 444–448
capsule, 436–439
genetics of production, 438
production of, 436–437
role in virulence, 438–439
catheter-associated UTI (CAUTI), 435–436, 445, 448–450
colonization and adherence, 442–445
fimbriae, 442–445
gene clusters, 442–444
role in virulence, 444
structure and genetics, 443–444
frequency of urinary tract colonization, 504
future perspectives on, 449–450
genome plasticity, 449
hypermucoviscous phenotype, 436, 438
inhibition biofilm formation, 248
intracellular bacterial communities (IBCs), 444, 450, 600
invasion of host cells, 372
LPS, 437
NDM-1 β-lactamase, 193
as opportunistic pathogen, 436
overview, 435–436
pyelonephritis, 150
renal and perirenal abscess, 151
siderophores, 440–441
urease, 441–442
virulence factors, 436–449
Koch’s postulates, molecular, 236, 264–265, 532
Kpc fimbriae, 444
Laboratory diagnosis, 43–48
dipsticks, 46–48
interpretation of culture results, 44–45
LE (leukocyte esterase), 46–48
nitrite testing, 46–48
pyuria, 45
rapid detection for bacteriuria, 45
urinary tract infection in children, 72–73
voided urine collection techniques, 43–44
voided urine contamination, 43–44
voided urine culture, 43
Lactic acid, lactobacillus production of, 81
Lactobacillus, 482–485
decline in low-estrogen state, 14, 82
as dominant vaginal microbe, 80–81
exclusion of uropathogens by, 81
hydrogen peroxide produced by, 80–81
L. acidophilus, 608
L. crispatus, 80–81, 83, 484–485, 608
L. gasseri, 484
L. iners, 482
L. jensenii, 80–81
nonoxynol-9 toxic effect on, 82
probiotic, 83, 485, 608
protective role, 14, 80–81, 471–472
Lactoferrin, 441, 509
Lamina propria, 565–568
Lateral gene transfer. See Horizontal gene transfer
Lectinophagocytosis, 438
Leptotrichia, 482
Leukocyte esterase (LE), 43, 46–48, 73, 460, 482
Levofloxacin
for bacterial prostatitis, 124–125
resistance, 191
for uncomplicated cystitis, 50–51
for uncomplicated pyelonephritis, 53–54
urinary-bactericidal titer (UBT), 143
for urosepsis, 143
Lipid A, 138
Lipocalin, 509
Lipopolysaccharides (LPS), 138
hemolysis (HylA), 268
Klebsiella pneumoniae, 437
LPS-smooth/-rough phenotypic variation, 337–338
pain induction by, 578–580
Proteus mirabilis swarming and, 395
Lipoprotein receptor-related proteins (Lrp), 243–244, 391–393
Lipoproteins, 660
Listeria monocytogenes, host cell invasion, 365–366
LL-37, 509, 556
Lon protease, 391
Loss-of-function mutations, 337
Lower urinary tract dysfunction, 71
Lrp, 243–244, 391–393
LuxS, 447
Lysoosomes, 368–369, 557
LysR regulators, 446–447, 391–393
LuxS, 447
Lysosomes, 368–369, 557
LysR regulators, 446
Macrophages
Enterococcus faecalis survival within, 468
response to bladder infection, 559–560, 562
uropathogenic E. coli (UPEC) survival within, 371
magA, 438
Malate, Proteus mirabilis swarming and, 397
Mannose-resistant Klebsiella-like (MR/K) hemagglutinin, 407
Mannose-resistant Proteus-like (MR/P) fimbriae assembly, 405
biofilm formation, 405
expression, 404–405
genetic organization, 403–404
role in infection, 405–407
Mannosides, 372, 605–606
Mast cell-derived adjuvants, 616
Mast cells, response to bladder infection, 559, 562
MCP-1 (monocyte-chemotactic protein-1), 535
mecA gene, 462
Mechanoreceptor, 568
Mechanosensitive afferent nerves, 568
Medullary sponge kidney, 10–11
Men
aging, asymptomatic bacteriuria in diagnosis, 89
incidence, 93–94
microbiology of, 99
prevalence, 92, 95
asymptomatic bacteriuria incidence, 93–94
prevalence, 92
clinical diagnosis in, 42
overview of clinical syndromes, 31
voided urine specimens for asymptomatic bacteriuria diagnosis, 89–90
Metabolism
during Proteus mirabilis swarming, 398–399
of uropathogenic E. coli (UPEC) during infection, 241–242
Metal acquisition systems. See also Iron acquisition
Proteus mirabilis, 413–416
zinc acquisition
Escherichia coli, 240–241
Proteus mirabilis, 396, 416
Metallo-β-lactamase, 193
Metalloproteases
metalloproteinase-9, 558, 560
Proteus mirabilis, 413, 416
Metals
competition for, 237
iron acquisition, 237–240
zinc acquisition, 240–241
Methicillin resistance, 462, 465
Methicillin-resistant S. aureus (MRSA), 70, 144–145, 465
Methyl-accepting chemotaxis, 388
MF59, 615
MHC class I molecules, curli adherence and, 293
Microbiology of bacteriuria, 97–100
Micturition, normal, 9–10
Midstream clean catch technique, 43–44
Mismatch-repair system, 338–339
MLEE (multilocus enzyme electrophoresis), 208
MLST. See Multilocus-sequence typing
Mobilome, 181
Molecular Koch’s postulates, 236, 264–265, 532
Molecular tools for risk assessment and prediction of UTI susceptibility, 543–544
Monocyte-chemotactic protein-1 (MCP-1), 535
Monophosphoryl lipid A (MPL), 615–616
Morganella morganii, 411
Motility, uropathogenic Escherichia coli (UPEC), 244–246
adherence and, 245
chemotaxis, 245
PapX as inhibitor of, 246
at population level, 245
regulation of flagellar, 242
MPL (monophosphoryl lipid A), 615–616
mrk-gene cluster, Klebsiella pneumoniae, 444
MrpA, 421, 623–624
MrpH, 421, 623–624
MrpJ, 410–411
MRSA (methicillin-resistant S. aureus), 70, 144–145, 465
MSCRAMMs, 301–307
Ace, 301–304, 306
assembly, 305
collagen hug model, 302–304
dock, lock, and latch model, 304–305
functions in uropathogenic bacteria, 305–307
overview, 301–302
SdrI, 307
structure, 302, 303
UafA, 304–305, 306
UafB, 306–307
Mucosal integrity, infection-associated disruption of, 510–511
Mucoviscosity-associated gene (magA), 438
Multidrug-resistant (MDR) pathogens, 590–591
emergence of, 180
enterococcal strains, 466
Escherichia coli, 556
Klebsiella pneumoniae, 448–449
Multilocus enzyme electrophoresis (MLEE), 208

Downloaded from www.asmscience.org by IP: 54.70.40.11
On: Thu, 06 Jun 2019 08:30:27
Multilocus-sequence typing (MLST)
E. coli isolates in prostatitis, 124, 125
ExPEC, 161–162
MutaFlor, 333
Mutation(s)
  pathoadaptive, 331–351
  synonymous and nonsynonymous changes, 340–341, 345–346, 350
Mutation rates
  asymptomatic bacteriuria strains, 345–346
  commensals, 345
  with mutator phenotype, 338
Shigella, 345
uropathogenic E. coli (UPEC) strains, 214–215, 345–346, 350
Mutator phenotype, 338–339
Mycobacterium tuberculosis, 70, 180
Myeloid differentiation primary response gene 88 (MYD88), 526–527, 531–533, 541, 604
Myeloperoxidase, 81
N-acetyl-neuraminic acid regulator (NanR), 249–250
Nalidixic acid, 190, 191
Na1P protease, 293, 296
Natural history of bacteriuria, 97–104
Natural killer cells, 560
NDM (New Delhi metallo) β-lactamases, 163, 193, 214
Necrotizing fasciitis, 151–152
Negative (purifying) selection, 341
Neisseria
  capsule biogenesis system of, 249
  N. meningitidis Na1P protease, 293, 296
Neomycin resistance, 196
Neonatal meningitis Escherichia coli (NMEC), 208
Neutrophils
  macrophage ingestion of apoptotic, 560, 562
  neutrophil-associated tissue damage, 558–562
  neutrophil-dependent clearance of infection, 536
  neutrophil-induced oxidative injury of renal cells, 513–514
  recruitment of, 508–509, 535–537
  response to bladder infection, 558, 561–562
  New Delhi metallo (NDM) β-lactamases, 163, 193, 214
NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells), 138–139, 508
Nissle-1917 strain, 333–334
Nitric oxide, 573
Nitrites, 43, 46–48, 73, 460
Nitrofurantoin, 193
Nitrofurantoin
  for asymptomatic bacteriuria, 105–106, 110
  creatinine clearance (CrCl) and, 50, 58
  for prophylaxis, 57–58
  for Proteus mirabilis, 419
  resistance
    mechanism, 193
    prevalence, 193–194
    side effect, 50–51, 58
  for uncomplicated cystitis, 49–51
  for UTI during pregnancy, 31
NMEC. See Neonatal meningitis Escherichia coli
NO1, 556, 561
Nonoxynol-9, 82
Non-ribosomal peptide siderophore system (Nrp), 414, 417
Norfloxacin
  for asymptomatic bacteriuria, 110
  for prophylaxis, 33
  resistance, 191
Nosocomial urinary tract infection, in children, 70
Novobiocin resistance, 462
Nrp (non-ribosomal peptide siderophore system), 414, 417
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), 138–139, 508
Nutraceuticals, 608–609
Nutrient requirements, uropathogenic Escherichia coli (UPEC), 236–241
Nutritional competence, 223
O-antigen
  loss of, 337–338
  as rheostat for LPS-induced pain, 578–580
Obstruction
  nerve, 512–513
  primary bladder-neck, 16
Obstructive nephron, 513, 516
Obstruction
  nephron, 512–513
  primary bladder-neck, 16
ureteral, 11–12
ureteropelvic-junction, 15
urosepsis and, 139–141
Occludins, 566
Oftloxacin resistance, 191
Oligella, 484
OM-89, 624–625
Opportunistic pathogens
features of, 332
Klebsiella pneumoniae, 436
uropathogenic E. coli (UPEC) as, 332–333
Opsonophagocytosis, 438, 464
Orchitis, clinical picture, 151
Ornithine, Proteus mirabilis swarming and, 397
Orthoptic bladder substitution, bacteriuria and, 93
Outer membrane, assembly of the pilus fiber at, 285–286
Outer membrane proteins, uropathogenic E. coli (UPEC), 248–249
Outer-membrane-associated adhesins of UPEC, 300
Outer-membrane iron receptors, 240
Outer-membrane vesicles (OMVs), 620
Overactive bladder, 573
OXA-derived β-lactamases, 192
P blood group
as pyelonephritis risk factor, 560
UTI susceptibility and, 538–539
P fimbriae, 7, 125, 128–129
innate immune activation, 532–533
mutation, 343
P blood group and UTI susceptibility, 538–539
uropathogenic E. coli (UPEC), 243–244
P pili
assembly, 596
functions, 289
pathogenesis, 597–598
vaccines targeting, 621–622
P1 (adenosine) receptors, 574
pAA virulence plasmid, 125
Pain
bacterial analgesia in the bladder, 580–581
bacterial-pain phenotypes, 582
central sensitization, 579–580
chronic from transient infection, 579–581
CNS circuits in cystitis pain, 581–582
future directions and implications, 582–583
inflammatory, 577–578
interstitial cystitis/bladder-pain syndrome, 569
LPS-induced, 578–580
pathophysiologial mechanisms, 569
TLR4-dependent UTI pain, 577–578, 583
UTI as visceral-pain model, 576–577
PAIs (pathogenicity islands), 70, 129, 183–186, 212, 220, 224, 243, 252–253, 335
p-amino benzoic acid (PABA), 189
PAML program, 214
PAMPs (pathogen-associated molecular patterns), 616
Pangenome, 209–210
pap operon, 213
PapA, 289
PapB, 244, 507
PapD chaperone, 285
PapDG vaccine, 621–622
PapE, 289
PapF, 289
PapG, 243, 289, 335, 506, 526, 532, 592, 597–598
antagonists, 606–607
mutation, 343
vaccines targeting, 621–622
PapI, 343
PapK, 289
PapX, 244, 246, 507
Pathoadaptive mutations
detection of, 348–350
functional analysis and, 346–348
 genetic mechanisms for, 336–348
in uropathogenic E. coli, 331–351
Pathogen-associated molecular patterns (PAMPs), 616
Pathogenesis
asymptomatic bacteriuria, 94–97
host factors, 94–95
organism factors, 95–97
chronic pelvic pain, 131–132
complicated UTI, 604–605
Enterococcus faecalis, 604–605
recent discoveries in, 591–605
uncomplicated UTI, 592–604
urinary tract infection in children, 70–71
uropathogenic E. coli (UPEC), 592–604
ascension to and colonization of kidneys, 603–604
central metabolism and two-component systems, 601–602
cyclic AMP, 599
escape from endocytic vesicle, 599
FimH, 595
IBCs, 599–601
metal ions, 602
modeling outcomes of acute cystitis, 602–603
P pili, 596–598
type 1 pili, 592, 595
vagina role in, 80
Pathogenicity islands (PAIs), 70, 129, 183–186, 212, 220, 224, 243, 252–253, 335
Pathophysio gram of pyelonephritis, 515–516
Pathophysiology
pyelonephritis, 503–517
of urosepsis, 137–139
PathoSystems Resource Integration Center (PATRIC), 351
Pattern-recognition receptors (PRRs), 508, 529, 559, 616
detection methods, 350–351
Postcoital prophylaxis, 56–57
Posterior fourchette-to-anus distance, 13
Postmenopausal women
  immune breakdown in, 560
  recurrent UTI in, 58–59
  vaginal microbiota alterations in, 81–82
Post-renal obstruction, urosepsis and, 139
Potassium sensitivity test, 575
Poultry, sources of ExPEC, 167–169
Pregnant women
  antimicrobial use in, 31–32
  asymptomatic bacteriuria, 31, 611
  diagnosis, 48–89
  incidence, 93
  microbiology of, 98
  morbidity, 102
  prevalence, 92
  screening for, 105–107
  treatment, 105–107
  group B Streptococcus (GBS) in, 32, 469–470
  physiology and anatomy changes, 15
  pyelonephritis, 31, 102, 105–107
Prevalence
  asymptomatic bacteriuria, 36, 91–93, 529
  prostatitis, 36
  uropathogenic Escherichia coli (UPEC)
    pathoadaptive mutations, 343–346
    virulence and fitness determinants, 594–595
  UTI in aging female, 13–14
  UTI in children, 69
Prevention of recurrent urinary tract infection, 36, 55–60
  antimicrobial prophylaxis, 56–58
  continuous prophylaxis, 57
  postcoital prophylaxis, 56–57
  self-diagnosis and self-treatment, 57–58
  special considerations about, 58
  antimicrobial-sparing approaches, 55
  attachment inhibitors, 60
  in postmenopausal women, 58–59
  probiotics, 59
  vaccines, 59–60
Prevotella, 482, 483
Primary bladder-neck obstruction (PBN0), 16
Probiotics, 75, 83, 608
  E. coli, 561
  Lactobacillus, 83, 485, 608
  Nissle-1917 strain, 333–334
Professional pathogens, 332
Progestosterone, 102
Promoter polymorphisms, 539–541
Prophage, horizontal gene transfer, 335
Prophylaxis
  antimicrobial, 56–58, 591
    in catheterized patients, 33
    continuous prophylaxis, 57
  postcoital prophylaxis, 56–57
  self-diagnosis and self-treatment, 57–58
  special considerations about, 58
  with vesicoureteral reflux, 75
  children, urinary tract infection in, 75
  cranberry products, 608–609
  Lactobacillus, 608
  postcoital, 56–57
  probiotics as, 608
  UTI in children, 75
Propionibacterium avidum, 478
Prostate massage, 151
Prostatic abscess, 151
Prostatitis, 121–132
  categories of syndromes, 121
  chronic, 129–132
  clinical picture of acute, 151
  E. coli in acute bacterial prostatitis, 121–132
  characteristics of E. coli isolates, 125–127
  clinical presentation, 124
  overview, 122
  in previously healthy young men, 123–126
  studies on, 122–123
  treatment, 124–125
  virulence, 123, 125–129
  Enterococcus, 466
  overview, 30
  prevalence, 36
  symptoms, 30
  treatment, 31
  Protease involved in colonization (Pic), 246–247
  Proteases, Proteus mirabilis, 413
  Protein involved in intestinal colonization (PicU), 265
  Protein-kinase C, 139
  Proteobactin, 414–417
  Proteus
    antimicrobial resistance, 48
    renal and perirenal abscess, 151
    UTI in children, 70
  Proteus mirabilis, 383–422
    adhesins, 280, 281, 623–624
    antimicrobial resistance, 145
    asymptomatic bacteriuria, 95, 97
    autotransporters, 295
    biofilms, 385, 405–406, 419
    catheter obstruction, 97
    characteristics of, 383
    clinical aspect of UTI, 419–422
    antibiotic resistance, 420
    prevention, 419
    treatment, 419–420
    urinary catheter biofilm formation, preventing, 421–422
    vaccine, 420–421
    disease, 383–384
    fimbriae, 14, 402–411, 623–624
Proteus mirabilis (continued)

ambient temperature fimbria (ATF), 409
conservation and expression of, 409–410
mannose-resistant Klebsiella-like (MR/K), 402–403, 407
mannose-resistant Proteus-like (MR/P), 402–407
Proteus mirabilis fimbria (PMF), 408–409
Proteus mirabilis P-like fimbria (PMP), 409
regulation of transition between swimming and swarming, 410–411
uroepithelial cell adhesin (UCA), 402–403, 407–408
vaccine potential of, 421
flagella, 386–388
antigenic variation, 387
characteristics, 386–387
constitutive elongation mutants, 391
contribution to swarming, 389–395
regulation, 387
role in virulence, 387–388
frequency of urinary tract colonization, 504
Iha, 300
incidence of UTI, 384
invasion of host cells, 372
MrpJ motility inhibitor, 246
pili, 281, 412
polymicrobial UTI, 461
quorum sensing, 398
swarming, 388–402
bull’s-eye pattern on media, 389
capsule and, 395–396
cellular invasion and, 399–400
Dienes line formation, 401–402
DisA, 393–394
DNA replication without septation during, 389
extracellular contributors to, 396–397
flagella contribution to, 389–395
\( \text{flhDC} \) regulation, 391
genes contributing to, table of, 392–393
glutamine, 396
Lon protease, 391
LPS and, 395
Lrp, 391–393
metal acquisition, 396
non-flagellar loci contributing to, 395–396
overview of, 388–389
putrescine, 396–397
role in virulence, 400
RppAB, 395
RsHA-RsBC, 394–395
RsmA/csrA, 394
switch between swimming and swarming forms, 390, 410–411
transcription and metabolism during, 398–399
Umo proteins, 394
WosA, 394
vaccines against, 623–624
virulence factors, 384–419
auto transporters, 411–412
biofilm, 405–406, 417, 419, 421–422
fimbriae, 402–411
flagella, 386–388
gene expression during UTI, 418–419
genome organization, 418
hemolysin, 412–413
identified by signature-tagged mutagenesis, 417–418
metal acquisition systems, 413–416
phosphate transport, 416–417
proteases, 413
swarming, 388–402
type IV pili, 412
urease, 384–386
Providencia stuartii, 385
asymptomatic bacteriuria, 97
polymicrobial UTI, 461
urinary stones, 461
PRRs (pattern-recognition receptors), 508, 529, 559, 616
Pseudomonas
asymptomatic bacteriuria, 97
UTI in children, 70
Pseudomonas aeruginosa
antimicrobial resistance, 48
autotrophs, 338
biofilms, 143
EstA autotransporter, 295–296
frequency of urinary tract colonization, 504
hospital-acquired UTIs, 28
inhibition biofilm formation, 248
LPS variation, 338
mucoid phenotype, 336
polymicrobial UTI, 462
urosepsis, 143
Pseudorabies virus, 581
PSM (phenol-soluble modulins), 464–465
Pta autotransporter, 412
PTK2, 533
PTX3 (pentraxin-related protein 3), 556–558
Pudendal nerves, 567
Putrescine, Proteus mirabilis swarming and, 396–397
P2X3, 568
Pyelitis, Corynebacterium urealyticum, 473
Pyelonephritis, 503–517
Actinobaculum schalii, 477
acute, 503, 515, 527
clinical diagnosis, 42
complicated pyelonephritis, clinical diagnosis, 42
incidence, 36
overview of clinical syndrome, 30
susceptibility, 527, 529–531, 536, 539–541
symptoms, 30, 527
treatment, 53–55
uncomplicated pyelonephritis, 42, 53–55
acute kidney injury (AKI), 513–514
asymptomatic bacteriuria, 29
bacterial colonization in renal tubular environment, 506
bacterial toxins and host responses, 506–508
chronic, 503
clinical diagnosis, 42
clinical picture, 150
defined, 503
differential diagnosis, 543
emphysematous, 150
future projections on, 515–517
Gardnerella vaginalis, 479
genetic risk factors, 35
group B Streptococcus, 469
innate immune responses, 508–510
inter-organ communication, 513
interpretation of urine culture results, 44
mucosal integrity disruption, 510–511
nephron-obstruction, 512–513
P blood group as risk factor for, 560
P fimbriae and type 1 fimbriae synergy, 506–507
pathophysiogram, 515
pathophysiology, 503–517
in pregnant women, 15, 31, 102, 105–107
prevention of dissemination, 511–512
Proteus mirabilis, 383
quantitative urine culture, 73
risk factors, 504
Staphylococcus saprophyticus, 462, 466
sterile, 479
symptoms, 503, 589
treatment, 514–515
acute uncomplicated pyelonephritis, 42, 53–55
in children, 74
urosepsis, 139
vaccine, 611, 617, 619–621
vesicoureteric reflux and, 71, 72
Pyonephrosis, 152
Pyuria, 460
asymptomatic bacteriuria, 90–91, 107
catheter-associated UTI (CAUTI), 468
in children, 73
Gardnerella vaginalis, 477
laboratory diagnosis, 45
prostatitis, 122, 124, 126
QepA1, 163
QseBC two-component system, 601
Quantitative urine culture, 44–45, 73, 88, 484
Quiescent intracellular reservoirs (QIRs), 8, 603
Quinolones
Proteus mirabilis, 419
resistance, 336
Quorum sensing
Klebsiella pneumoniae, 446
Proteus mirabilis, 398
quorum-sensing (Qse) system, 251
R (resistance) plasmids, 183–184, 195–196
Rab35, 369
Rab27b, 366–367, 533
RAB27b+ vesicles, 557
RAC1, 533
Random-amplified polymorphic DNA (RAPD), 208, 217
RANTES promoter variant, 540
Rapid detection strategies for bacteriuria, 45
RarA, 449
rbs operon, 223
RcsBC, 394–395
Receptor analogues, to prevent bacterial attach- ment, 542
Receptor-mediated uptake of heme, 239
Recombination, role in genome evolution, 209
Recurrent urinary tract infections
asymptomatic bacteriuria strains as therapy, 607–608
in children, 69–70
defined, 35
genetic predisposition to, 35
incidence of, 590
overview, 35–36
prevention, 36, 55–60
antimicrobial prophylaxis, 56–58
antimicrobial-sparing approaches, 55
attachment inhibitors, 60
in postmenopausal women, 58–59
probiotics, 59
vaccines, 59–60
protective immunity and, 610–611
Reductive evolution, 529
Refux. See Vescicoureteral reflux
Reinfection, 35
Relapse, 63
Renal abscess, 150–151
Renal function, impairment in urosepsis, 139–141
Renal papillae, 4
Renal pelvis, 4
Renal pelvis aspiration, 90
Renal scarring, 72, 75, 100, 509, 513, 531, 540, 590, 603
Renal transplant patients
asymptomatic bacteriuria, 29
bacteriuria, 104, 109–110
Renal-cortical scintigraphy, 74–75
Repair, urothelial, 570–572
Repeats-in-toxin (RTX) family, 25, 300–301
E. coli hemolysin, 264–269
UpxA, 269
Resiniferatoxin, 572
Resistance, urosepsis treatment and, 144
Reverse vaccinology, 622–623
RfaH, 248, 269
Rheumatoid arthritis, 384
Rho GTPases, 246–247
Ribonuclease 7, 556
Ribosomal DNA (rDNA) restriction fragment-length polymorphism analyses, 208
Risk assessment, molecular tools for, 543
Risk factors, 35, 590
Risk increase for asymptomatic bacteriuria, 95
RmpA, 438
RmtB, 163
RNA polymerase II, 541–542
RNA-seq, 254
RpoS, 223
RppAB, 395
Rga, 467
RsbA, 394–395
RseA, 250
RsmA, 394
RTX family of toxins. See Repeats-in-toxin (RTX) family
S fimbriae, 244, 539
S pili, vaccine targeting, 622
SadA, 299
Salmochelin, 126, 128, 238–239
in E. coli prostatitis, 130
uropathogenic E. coli (UPEC), 534, 602
Salmonella
curli, 289, 291
SadA, 299
serovar Typhimurium
cellular invasion, 399
iron chelation, 414
Sit genes, 240
swarming by, 389
typhi, cellular invasion and, 399
Schistosomiasis haematobium, 70
SdrG, 301, 304
SdrI, 307, 463
Sec systems, 463
Secondary vesicoureteric reflux, 15
Secreted autotransporter toxin (Sat), 246–247, 265, 271
Selfish DNA, 209
Self-preservation and nutritional competence (SPANC), 223
Sensation within the urinary tract, 565–583
Sepsis. See also Urosepsis
classifications of, 135
cytokines as markers, 138
diagnostic criteria for, 136, 137
epidemiology of, 136–137
Surviving Sepsis Campaign guidelines, 147–148
Septic shock
clinical diagnostic criteria of, 137
prevention, 152
Serine-protease autotransporter toxins of Enterobacteriaceae (SPATE), 247, 271
Serratia marcescens
antimicrobial resistance, 145
swarming, 398
Sewage, as ExPEC reservoir, 164
Sexual activity
as asymptomatic bacteriuria risk factor, 94
Gardnerella vaginalis transmission, 479
postcoital prophylaxis, 56–57
as UTI risk factor, 236
Shear stress for the renal tubule, 506–507
Shigella
as professional pathogen, 332
S. flexneri, infectious dose of, 334
SHV-1 β-lactamases, 192
Siderophores
E. coli prostatitis, 125–129, 130
Klebsiella pneumoniae, 440–441
pathogenesis, 602
Proteus mirabilis, 414–415
uropathogenic E. coli (UPEC), 238–239, 534, 602
Sigma E, 250
Signaling, 566, 570, 572–575
Signature-tagged mutagenesis (STM)
Klebsiella pneumoniae biofilm gene identification,
446–448
Proteus mirabilis, 388, 417–418
Silver compounds, 197
Single-nucleotide polymorphisms (SNPs), 17, 337
SIRS (systemic inflammatory response syndrome),
135, 138
Sit system, 240
16S rRNA methylation, 196
Small colony-forming variants, 338
Sneathia, 483
SNPs (single-nucleotide polymorphisms), 17, 337
SolcoUrovac, 617–618
Soluble tumor necrosis factor receptors (sTNFR-1),
102
Sortases, 305, 310, 604–605
Enterococcus faecalis, 467
Staphylococcus saprophyticus, 463
SPA (suprapubic-bladder aspiration) in children,
72–73
Space of Retzius, 5
SPANC (self-preservation and nutritional competence), 223
SPATE (serine-protease autotransporter toxins of Enterobacteriaceae), 247, 271
Spermicide use, as risk factor for asymptomatic bacteriuria, 94
Spinal cord injuries, asymptomatic bacteriuria and, 109
incidence, 93–94
prevalence, 93
SraP, 463
Ss1E, 623
Ssp, 463
SssF, 463
Staphylococcus, 483, 484
S. aureus
antimicrobial resistance, 144–145, 180
autotrophs, 338
ClfA, 301–302, 304
Cna, 301–302, 304
inhibition biofilm formation, 248
methicillin-resistant, 70, 144–145, 465
phenol-soluble modulin (PSM), 465
renal and perirenal abscess, 151
SraP, 463
α-toxin, 268–269
toxin A, 138
urosepsis, 143
UTI, 70, 465
vancomycin-resistant S. aureus (VRSA), 144–145
S. epidermidis, 465
inhibition biofilm formation, 248
SdrG, 301, 304
S. saprophyticus, 459–466
adhesins, 281, 306–307
antibiotic resistance in, 462
in children, 70
community-acquired UTIs, 301
epidemiology of UTI, 462–463
frequency of urinary tract colonization, 504
host response to UTI, 465–466
invasion of host cells, 372
laboratory models of UTI, 461
polymicrobial UTI, 461
SdrI, 307
UafA, 304, 306
UafB, 306–307
virulence factors, 463–465
STM. See Signature-tagged mutagenesis
STNFR-1 (soluble tumor necrosis factor receptors), 102
Streptococcus, 483, 484
S. pyogenes Spy0128 pilin, 304
S. suis, 606
viridans streptococci group, urinary tract colonization by, 504
Streptomycin
discovery, 195
resistance, 196
Stress, urothelial consequences of, 571
Stretch-induced exocytosis, 569–570
Strovac, 617–618
Struvite crystals, Corynebacterium urealyticum, 473
Substance P, 568, 572
Sulfamethoxazole and trimethoprim
for asymptomatic bacteriuria, 106, 108, 109
for bacterial prostatitis, 124–125
mode of action, 189
for prophylaxis, 56–58
for prostatitis, 31
for Proteus mirabilis, 419
resistance, 48–49, 51, 58, 124, 213, 219, 419–420,
606
mechanism, 189–190
prevalence, 190
for uncomplicated cystitis, 49–51
for uncomplicated pyelonephritis, 53–54
for UTI children, 74
Sulfamethoxazole and trimethoprim (SMZ-TMP) resistance, 419–420
Sulfamethoxazole-resistance genes, 182
Sulfonamide resistance, 124, 472
Suprapubic aspirate, 72–73, 89, 90
Surviving Sepsis Campaign, 147–148
Susceptibility to urinary tract infection
antimicrobial peptides, 538
asymptomatic bacteriuria, 529, 532, 534, 539–541
chemokine receptors and, 535, 537
cytokine response, 534–535
definitions, 525–529
innate immune activation and, 529–534
autotransporters, 534
curli, 534
iron acquisition systems, 534
P fimbriae, 532–533
TLR4, 531–532
toxins, 534
type 1 fimbriae, 533–534
Irf3 or IfnB defects, 537
molecular determinants and genetics, 538–541
adaptor gene polymorphisms, 539
CXCRI expression, 540
geneic variation, 539–541
IRF3 expression, 540
low TLR4 expression, 539
promoter polymorphisms, 539–541
receptors for bacterial adhesins, 538–539
molecular tools for risk assessment and predictions, 543–544

S. gordonii GspB, 463
S. pneumoniae RrgA, 304, 467

Downloaded from www.asmscience.org by
IP: 54.70.40.11
On: Thu, 06 Jun 2019 08:30:27
Susceptibility to urinary tract infection (continued)
neutrophil recruitment, 535–536
pyelonephritis, 527, 529–531, 536, 539–541
therapeutic approaches to modify, 542–543
deliberate establishment of asymptomatic bacteriuria, 542
gene therapy, 542
receptor analogue, 542
vaccination, 543
Tlr5, Tlr11, Thp, and COX2 defects, 537–538
Swarming motility of Proteus mirabilis, 383, 388–402
Systemic inflammatory response syndrome (SIRS), 135, 138
Systems vaccinology, 616–617
T cells, γβ, 560
TA (toxin–antitoxin) systems, 369
TaaP autotransporter, 412
Tamm–Horsfall protein (THP), 509, 533, 537–538
TCA (tricarboxylic acid) cycle, 601
TcpC, 527, 604
Temperature-sensitive hemagglutinin (Tsh), 247
Tendonitis, fluoroquinolones and, 58
Tension receptors, 568
Tetracyclines
mode of action, 194
resistance, 124, 182, 420
mechanism, 194–195
prevalence, 195
TGF (tubuloglomerular feedback), 513
TGF-β1 polymorphism, 541
Tigecycline, 194
Tight junctions, 7, 566, 575
TimeZone software package, 350
TIR domain proteins, 541
TIR domain-containing adaptor adaptor protein (TIRAP), 531–532
Tissue microbiology, 516–517
TNF-α (tumor necrosis factor-α), 138–139, 511, 514, 560
Toll-like receptors (TLRs)
in Enterococcus UTIs, 466–467
as pattern-recognition receptors (PRRs), 616
role in pyelonephritis response, 508
TcpC impairment of, 527
TLR1, 534, 560
TLR2, 534
TLR4, 526, 530–533, 556–557, 560, 592, 599, 604
low expression in patients with ABU, 539
MPL as agonist, 615
promoter variation, 539
recognition of LPS lipid A, 619
TLR4-dependent host defenses, 370–371
TLR4-dependent UTI pain, 577–578, 583
TLR5, 534, 537–538, 561
TLR11, 537–538
TonB system, 602
Klebsiella pneumoniae, 440–441
TonB-dependent receptors, in Proteus mirabilis, 414–415
TonB-ExbB-ExbD complex, 237
Topical vaginal estrogen therapy, 82
Torsades de pointe, fluoroquinolones and, 58
TosA, 252, 269, 300–301
Toxic-shock syndrome toxin 1, 138
Toxin-antitoxin (TA) systems, 369
Toxins
autotransporter, 247
E. coli prostatitis isolates, 125–129
pyelonephritis and, 507–508
RTX family, 252
uropathogenic E. coli (UPEC), 246–247, 263–272, 604–605
actions and epidemiology, table of, 265
autotransporter family, 271
cytotoxic necrotizing factor type 1 (CNF1), 265, 269–270
hemolysin (HylA), 264–269, 507–508
PicU, 265
secreted autotransporter toxin (Sat), 265, 271
type V secretion family, 270–271
Vat, 265
Toxoid, 619–620
TraDIS (transposon-directed insertion-site sequencing), 255
TRAM, 526, 531–533, 539
Transcription, during Proteus mirabilis swarming, 398–399
Transcriptional profiling, 253–254
Transcriptomics
in pyelonephritis, 513
uropathogenic E. coli (UPEC), 253
Transfer RNA (tRNA) genes, 252
Transferrin, 441
Transitional stratified epithelium, 504
Transposase, 184
Transposon mutagenesis, 254
Transposon-directed insertion-site sequencing (TraDIS), 255
Transposons, 181–182, 189–190, 195–196
Transurethral–bladder catheterization, in children, 72–73
Treatment, 48–55
acute uncomplicated cystitis, 49–53
acute uncomplicated pyelonephritis, 53–55
antimicrobial resistance, 48–49, 179–198
anti-virulence therapies, 605–609
asymptomatic bacteriuria, 104–110
after invasive genitourinary procedures, 109
children, 104–105
diabetic patients, 107
elderly institutionalized patients, 107
indwelling urethral catheter patients, 107–108
INDEX

older women, 107
pregnant women, 105–107
renal transplant patients, 109–110
spinal cord injury patients, 109
bacterial prostatitis, 124–125
catheter-associated UTI (CAUTI), 609
chaperone/usher pathway inhibitors, 607
in children, 73–74
cranberry products, 608–609
curtildes, 607
drug and vaccine development, 589–626
ibuprofen, 603
intravesicular therapy, 607–608
need for new therapies, 589–591
nutraceuticals, 608–609
PapG antagonists, 606–607
pilicides, 607
probiotics, 608
pyelonephritis, 514–515
self, 57–58
vaccines (see Vaccines)
Tricarboxylic acid (TCA) cycle, 601
TRIF-related adaptor molecule (TRAM), 526, 531–533, 539
Trigone of the bladder, 5
Trimethoprim resistance, 476
Trimethoprim-sulfamethoxazole. See Sulfamethoxazole and trimethoprim
Tubular necrosis, 513
Tubuloglomerular feedback (TGF), 513
Type V secretion system, 293
autotransporters in Proteus mirabilis, 411–412
toxins in, 270–271
Type IV secretion system, 534
Type IV pili, 243, 412
Type 1 fimbriae
innate immune-response activation by, 533–534
Klebsiella pneumoniae, 442–445
mutations, 341–342, 346–348
phase variation, 507
Salmonella, 443
synergy with P fimbriae, 506–507
uropathogenic E. coli (UPEC), 243, 506–507
Type 1 pili
bladder cell invasion and, 360–361, 365–368, 371
functions, 287–288
pathogenesis, 592, 595
structure, 286–287
vaccines targeting, 620–621
Type VI secretion system, 401–402
Type 3 fimbriae, of Klebsiella pneumoniae, 442–445
Type III secretion system, 251, 418
Type II toxin-antitoxin systems (TA), UPEC, 534
UafA, 301–304, 306, 463
UBT (urinary-bactericidal titer), 143
UCA (uroepithelial cell adhesin), 407–408
UcaA, 624
Umo proteins, 394
Uncomplicated urinary tract infection
defined, 28
demographics of, 459
Gram-positive uropathogens, 459
overview of clinical syndrome, 29
risk factors, 590
symptoms, 459
UPEC. See Uropathogenic Escherichia coli
UPEC-specific genes, search for, 211–214
UPJO (ureteropelvic-junction obstruction), 15
UP1a, 360, 365–368
Upper urinary-collecting system, 4
UpxA, 269
Urease
Corynebacterium urealyticum, 473
Klebsiella pneumoniae, 441–442
genetics and structure, 441
role in virulence, 441–442
Proteus mirabilis, 383, 384–386
Staphylococcus aureus, 465
Staphylococcus saprophyticus, 463
virulence mechanism, 385
Ureter, 4
obstruction, 11–12, 139–140
urine transport, 9
Ureteral stents, bacteriuria and, 93
Ureteropelvic junction, 4
Ureteropelvic-junction obstruction (UPJO), 15
Ureterovesical junction, 4, 5, 71
Urethra
anatomy, 5–6
length, 13, 27, 236
Urethral catheterization, interpretation of urine culture results from, 44–45
Urethra-to-anus distance, 13
Urinary continence, female
in aging female, 13–14
hammock theory, 14
integral theory, 13–14
Urinary malakoplakia, 371
Urinary retention, chronic, 13
Urinary stones, 461
Proteus mirabilis and, 385–386, 420
Staphylococcus saprophyticus, 463–464
Urinary-bactericidal titer (UBT), 143
Urinary-urgency incontinence (UUI), 481, 484
Urine, uropathogenic Escherichia coli growth in,
236–237
Urine cultures
in children, 72–73
expanded-quantitative urine culture (EQUC), 484
interpretation of results, 44–45
quantitative, 44–45, 73, 88, 484
voided urine, 43
Urinary interleukin-8 (IL-8), 91
Urine sample
collection in children, 72–73
contamination, 480–481
Urine transport, 9–10
Uro-adherence factor A (UafA), 301–304, 306, 463
Uro-adherence factor B (UafB), 463
Uroepithelial cell adhesin (UCA), 407–408
Uromune, 624
Uropathogenic Escherichia coli (UPEC), 208. See also Escherichia coli
adhesins, 70–71, 506–507, 592–599
allelic variation under positive selection, 214–215
antimicrobial resistance, 179–198
asymptomatic bacteriuria, 96
attachment, 60
autotransporter adhesins, 298–300
in chronic pelvic pain syndrome, 129–132
curli, 290, 292–293
cytokine response to infection, 534–535
dispersal, 600
ecological cycle, 333
escape from endocytic vesicle, 599
expulsion of internalized, 599
fimbriae, 242–244, 506–507
FIC fimbria, 244
gene clusters, 244, 251
lack of gene expression in vivo, 253–254
P fimbriae, 7, 243–244, 506–507, 532–533
phase variation, 507
pilicides, 244
Pix fimbria, 244
S fimbria, 244
type 1 fimbriae, 243, 245, 506–507
Yad fimbria, 244
Ygi fimbria, 244
frequency of urinary tract colonization, 504
genome sequences, 251–253
heterogeneity of strains, 610
incidence of UTI, 556, 590
initiation of the innate immune response by,
526
intraocular bacterial communities (IBCs), 7, 35,
236, 239, 246, 249–250, 361–364, 369–370, 571, 591, 599–600
invasion of host cells, 359–372
antibacterial defenses and liabilities, 370–371
fates of intracellular UPEC, 360–363
intraocular bacterial communities (IBCs),
361–364, 369–370
of kidney cells, 371
mechanisms of bladder cell invasion, 365–368
regulation of intracellular growth and persistence, 368–369
relevance to UTIs, 364–365
targeting intracellular pathogens, 372
iron acquisition, 238–239, 534, 602
lysosome neutralization, 557
as a model organism for uncomplicated UTI, 591
motility, 244–246
adherence and, 245
chemotaxis, 245
PapX as inhibitor of, 246
at population level, 245
regulation of flagellar, 242
multi-drug resistance, 591
mutation rate, 214
nutrient requirements, 236–241
competition for metals, 237
growth in urine, 236–237
iron acquisition, 237–240
zinc acquisition, 240–241
as opportunistic pathogen, 332–333
origin of strains, 216–217
pathoadaptive mutations, 331–351
amplification of gene copies, 337
detection of, 348–350
evidence of occurrence, 337–338
functional analysis of traits, 346–348
gene inactivation, 336–337, 339–340
genetic variation, 337, 340
genome instability, 339
genome-wide screens for prevalence of,
343–346
horizontal gene transfer compared, 336
mutator phenotype, 338–339
phenotypic variations, observations of,
337–338
pathogenesis, 592–604
ascension to and colonization of kidneys,
603–604
central metabolism and two-component systems,
601–602
cyclic AMP, 599
escape from endocytic vesicle, 599
FimH, 595
IBCs, 599–601
metal ions, 602
modeling outcomes of acute cystitis, 602–603
INDEX

P pili, 596–598
  type 1 pili, 592, 595
phylogeny and virulence factors, 217–218
pili function, 287–289
  P pili, 289
type 1 pili, 287–288
polymeric UTI, 461–462
prostatitis, 125–127, 130–131
pyelonephritis, 150, 505–513
QIR, 603
relationship to APEC and NMEC strains, 216
strains both resistant and virulent, 219
strains infecting infants, 218–219
toxins, 263–272, 507–508
PicU, 265
secreted autotransporter toxin (Sat), 265, 271
type V secretion family, 270–271
Vat, 265
transcriptional control of the innate immune response to, 530
uroplakin interaction, 7
urothelial damage, 575–578
urothelium interactions, 571, 575–579
UTI in children, 70–71
vaccines, 60, 612–623
virulence and fitness determinants, 235–255
  autotransporter, 534
  biofilm, 247–248
  capsule, 249–250
curl, 534
  flagella, 534
gene expression in vivo, 253–254
genome sequences, 251–253
  global regulators of gene expression, 250–251
  innate immunity induction by, 534
metabolism, 241–242
motility, 244–246
nutrient requirements, 236–241
outer membrane proteins, 248–249
overview, 236
P fimbriae, 7, 506–507, 532–533
pathogenesis, 592–599
  phylogeny and, 217–218
prevalence and sites of action, 594–595
siderophores, 534
  surface structures, 242–244
toxins, 246–247, 534
Uroplakins, 6–8, 360, 365–368, 533, 555, 566, 571, 576, 595
Urosepsis, 135–153
Actinobaculum schaali, 477
algorithm for management of, 148–150
antimicrobial therapy, 141–147
  aminoglycosides, 142–143
  bacterial spectrum of pathogens, 143–144
  beta-lactams, 142
  biofilm infection, 143
  fluoroquinolones, 142–143
  pharmacokinetic/pharmacodynamics and, 142
selection of antimicrobials for empiric therapy, 144–147
clinical pictures of severe urogenital infections, 150–152
  acute prostatitis, 151
cavernitis, 151
  cystitis, 150
  epididymitis/orchitis, 151
  Fournier’s gangrene, 151–152
  prostatic abscess, 151
  pyelonephritis, 150
  renal and perirenal abscess, 150–151
cytokines as markers, 138
definition, 135–136
diagnostic criteria of sepsis and septic shock, 137
epidemiology, 136–137
Gardnerella vaginalis, 479
  neuro-endocrine axis and, 139
overview, 30
pathophysiology, 137–139
prevention, 152
renal function alterations, 139–141
Surviving Sepsis Campaign (SSC), 147–148
treatment, 515
Uroseptic shock, 30
Urostim, 624
Urothelial plaques, 7
Urothelial-cell turnover, 7
Urothelium, 6
  barrier function, 569
  cells and repair, 570–572
damage during UTI, 575–576
  FimH mediation of UPEC adherence to, 595
functioning, 566
  signaling, 566, 572–575
structure of, 565–566
turnover rate, 570
Urovac, 617–618, 625
UroVaxom, 624
Urvakol, 624
Ushers, 286–287, 443
UUI (urinary-urgency incontinence), 481, 484
VacA cytotoxin, 293
Vaccines
candidate vaccines, table of, 612–613
challenges in developing, 610–617
  adjuvant choice, 615–616
Vaccines (continued)

choice of immunogens, 611, 614–615
choice of recipients, 611
recurrent UTI and protective immunity, 610–611
route of administration, 615

Enterococcus vaccines, 624
ExPEC, 170
group B Streptococcus, 470
historical perspective, 609–610
iron receptors as candidates for, 240
OM-89/UroVaxom, 624–625
P pili, 289, 621
Proteus mirabilis, 420–421, 623–624
pyelonephritis, 611
reverse vaccinology, 622–623
specific-antigen vaccines in development, 611, 614, 619–623
conjuge vaccines, 619–622
FimH, 620–621
P pili, 621
PapDG vaccine, 621–622
pilus as candidates, 620–622
reverse vaccinology, 622–623
subunit vaccines, 614, 622–623
toxoid vaccines, 620
susceptibility to UTI and, 543
systems vaccinology, 616–617
uropathogenic E. coli (UPEC), 612–623
whole-cell vaccines in development, 611, 617–619
attenuated vaccines, 619
CP923, 618–619
inactivated vaccines, 617
SolcoUrovac, 617–618
StroVac, 617–618

Vacuolating autotransporter toxin (Vat), 265

Vagina, 6
protective role of lactobacilli in, 80–81
role in the pathogenesis of urinary tract infection, 80

Vaginal estrogen treatment, 36, 609
Vaginal Lactobacillus suppositories, 608

Vaginal microbiota, 79–83
alterations associated with antimicrobial therapy, 82
alterations associated with loss of estrogen, 81–82
alterations associated with UTI, 81
bacterial vaginosis, 471–472
clinical implications, 82–83
contraceptive method effect on, 82
protective role of lactobacilli, 80–81

Vancomycin resistance, 145, 466
Vancomycin-resistant S. aureus (VRSA), 144–145
Variceme Project, 351

Vasoactive-intestinal polypeptide (VIP), 568
Vat (vacuolating autotransporter toxin), 265
VEGF-promoter variants, 541

Veillonella, 483
Vesicoureteral junction, 100
Vesicoureteral reflux, 4, 5, 12, 590, 611
antimicrobial prophylaxis, 75
in children, 70, 71–72, 100, 105
primary, 71–72
as pyelonephritis risk factor, 504
secondary, 72
Vesicular exocytosis, 573
Vesicular recycling, 569
Vesicular trafficking, 8
VIP (vasoactive-intestinal polypeptide), 568
Viridans streptococci group, urinary tract colonization by, 504

Virulence
acute prostatitis E. coli, 123, 125–129
chronic prostatitis E. coli, 130
determinants of uropathogenic E. coli (UPEC), 235–255
evolution of
 genetic mechanisms, 333–336
 horizontal gene transfer, 335–336
 pathoadaptive mutations, 336–351
extraintestinal, 219–221
“by-product of commensalism” hypothesis, 224
clinical correlation, 220–221
hierarchical organization of factors involved, 221–222
intrinsic virulence, 220–221
measuring virulence, 219–220
Proteus mirabilis, 384–419

Virulence factors. See also specific virulence factors
acquisition of, 334
adhesins, 334–335
Enterococcus faecalis urinary tract infection, 466
group B Streptococcus, 470–471
horizontal gene transfer and, 335–336
Klebsiella pneumoniae, 436–449
phylogeny, correlation with, 217–218
Staphylococcus saprophyticus UTI, 463–465
uropathogenic E. coli (UPEC), 130, 592–599
Visceral pain, UTI as model of, 576–577
Visceral-pain hypersensitivity, 569
Voided urine specimens
asymptomatic bacteriuria, 88–90
men, 89–90
women, 88–89
collection techniques, 43–44
contamination, 88–89
Voiding cystourethrography, 74
Voiding dysfunction, 16, 504
VRSA (vancomycin-resistant S. aureus), 144–145

Waterways, E. coli in, 165
Whole-cell vaccines in development, 611, 617–618
Whole-genome sequencing, 45
Wildlife, as *E. coli* reservoir, 165
Wolffian ducts, 5
Women
    aging female
        anatomy and physiology, 13–14
        asymptomatic bacteriuria, 89, 92–95, 99
        immune breakdown in, 560
        incidence of UTI, 79
        UTI prevalence in, 13–14
    asymptomatic bacteriuria in aging
        diagnosis, 89
        incidence, 93–94
        microbiology of, 99
        prevalence, 92, 94–95
    asymptomatic bacteriuria in healthy
        microbiology of, 98
        morbidity, 101
        treatment, 105
    lifetime risk of UTI, 79
    postmenopausal
        immune breakdown in, 560
        recurrent UTI in, 58–59
        vaginal microbiota alterations in, 81–82
    pregnant
        antimicrobial use in, 31–32
        asymptomatic bacteriuria, 31, 611
            diagnosis, 88–89
            incidence, 93
    microbiology of, 98
    morbidity, 102
    prevalence, 92
    screening for, 105–107
    treatment, 105–107
    group B *Streptococcus* (GBS) in, 32, 469–470
    physiology and anatomy changes, 15
    pyelonephritis, 31, 102, 105–107
    voided urine specimens for asymptomatic
        bacteriuria diagnosis, 88–89
    WosA, 394

*Xenorhabdus nematophila*, 411

Yad fimbriae, 244
YadA adhesin, 295
*Yersinia*
    *Y. pestis* YadA adhesin, 295
    *Y. pseudotuberculosis* invasion protein, 300
*Yersiniabactin*, 126, 128–129, 238–239, 253, 534, 602
Ygi fimbriae, 244

ZapA, 391, 398, 413, 416, 420
Zinc acquisition
    *Escherichia coli*, 240–241
    *Proteus mirabilis*, 396, 416
ZnuACB system, 241–242
Zonal-Phylogeny analysis, 350